Details of the Drug

General Information of Drug (ID: DMINOX3)

• Drug Name: Vincristine
• Synonyms: LCR; Leurocristine; Marqibo; Oncovine; Tecnocris; VCR; VIN; Vincasar; Vincristina; Vincristinum; Vincrstine; Vincrystine; Vinkristin; Indole alkaloid; Liposomal Vincristine; Onco TCS; Vincristina [DCIT]; Oncovin (TN); Tecnocris (TN); Vincristine (INN); Vincristine [INN:BAN]; Vincristinum [INN-Latin]; Lilly37231 (1:1 sulfate salt); Oncovin (1:1 sulfate salt); Vincasar (1:1 sulfate salt); Vincrex (1:1 sulfate salt); Vincaleukoblastine, 22-oxo-22-Oxovincaleukoblastine; Z-D-Val-Lys(Z)-OH; 22-Oxovincaleukoblastine

Indication

Disease Entry	ICD 11	Status	REF
Acute lymphoblastic leukaemia	2A85	Approved	[1]
Adult kidney Wilms tumor	N.A.	Approved	[2]
Beckwith-Wiedemann syndrome	N.A.	Approved	[2]
Burkitt lymphoma	N.A.	Approved	[2]
Central nervous system neoplasm	N.A.	Approved	[2]
Childhood acute lymphoblastic leukemia	N.A.	Approved	[2]
Childhood kidney Wilms tumor	N.A.	Approved	[2]
Hamartoma	N.A.	Approved	[2]
Kidney neoplasm	N.A.	Approved	[2]
Leukemia	N.A.	Approved	[2]
MALT lymphoma	N.A.	Approved	[2]
Nodal marginal zone lymphoma	2A85.0	Approved	[2]
Plasma cell myeloma	2A83.1	Approved	[2]
Primitive neuroectodermal tumor	N.A.	Approved	[2]
Splenic marginal zone lymphoma	N.A.	Approved	[2]
Testicular lymphoma	N.A.	Approved	[2]
Wilms tumor	N.A.	Approved	[2]
Classic Hodgkin lymphoma	N.A.	Investigative	[2]
Follicular lymphoma	2A80	Investigative	[2]
Neuroblastoma	2D11.2	Investigative	[2]

• Therapeutic Class: Anticancer Agents
• Affected Organisms: Humans and other mammals
• ATC Code:
  L01CA02: Vincristine
  L01CA: Vinca alkaloids and analogues
  L01C: PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS
  L01: ANTINEOPLASTIC AGENTS
  L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 2:
  Molecular Weight (mw); 825
  Logarithm of the Partition Coefficient (xlogp); 2.8
  Rotatable Bond Count (rotbonds); 10
  Hydrogen Bond Donor Count (hbonddonor); 3
  Hydrogen Bond Acceptor Count (hbondacc); 12
• ADMET Property:
  BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
  Clearance: The drug present in the plasma can be removed from the body at the rate of 2 mL/min/kg [4]
  Elimination: 15% of drug is excreted from urine in the unchanged form [3]
  Half-life: The concentration or amount of drug in body reduced by one-half in 5 minutes (alpha), 2.3 hours (beta), and 85 hours (gamma) [4]
  Metabolism: The drug is metabolized via the hepatic []
  Unbound Fraction: The unbound fraction of drug in plasma is 0.4% [4]
  Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 2.4 L/kg [4]
  Water Solubility: The ability of drug to dissolve in water is measured as 10 mg/mL [3]
• Chemical Identifiers:
  Formula: C46H56N4O10
  IUPAC Name: methyl (1R,9R,10S,11R,12R,19R)-11-acetyloxy-12-ethyl-4-[(13S,15S,17S)-17-ethyl-17-hydroxy-13-methoxycarbonyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9-tetraen-13-yl]-8-formyl-10-hydroxy-5-methoxy-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraene-10-carboxylate
  Canonical SMILES: CC[C@@]1(C[C@@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O
  InChI: InChI=1S/C46H56N4O10/c1-7-42(55)22-28-23-45(40(53)58-5,36-30(14-18-48(24-28)25-42)29-12-9-10-13-33(29)47-36)32-20-31-34(21-35(32)57-4)50(26-51)38-44(31)16-19-49-17-11-15-43(8-2,37(44)49)39(60-27(3)52)46(38,56)41(54)59-6/h9-13,15,20-21,26,28,37-39,47,55-56H,7-8,14,16-19,22-25H2,1-6H3/t28-,37+,38-,39-,42+,43-,44-,45+,46+/m1/s1
  InChIKey: OGWKCGZFUXNPDA-XQKSVPLYSA-N
• Cross-matching ID:
  PubChem CID: 5978
  ChEBI ID: CHEBI:28445
  CAS Number: 57-22-7
  UNII: 5J49Q6B70F
  DrugBank ID: DB00541
  TTD ID: D09QVV
  VARIDT ID: DR00143
  INTEDE ID: DR1692
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Tubulin beta (TUBB)	TTYFKSZ	NOUNIPROTAC	Modulator	[5]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Multidrug resistance-associated protein 2 (ABCC2)	DTFI42L	MRP2_HUMAN	Substrate	[6]
Multidrug resistance-associated protein 1 (ABCC1)	DTSYQGK	MRP1_HUMAN	Substrate	[7]
Breast cancer resistance protein (ABCG2)	DTI7UX6	ABCG2_HUMAN	Substrate	[8]
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[9]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[10]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Substrate	[10]
Cytochrome P450 3A7 (CYP3A7)	DERD86B	CP3A7_HUMAN	Substrate	[11]

Experimental Cancer Drug Sensitivity Information

Cancer Drug Sensitivity Data Curated from 40 Cell Line(s) in Bone Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
RPMI-3460/CS1	GDSC2	-0.5	14.3535	-6.6104	39.8798
ES7	GDSC2	-8.8462	-3.1883	-8.9343	84.7676
A-673	GDSC2; CTRP2	-8.1904	-2.7307	-8.2013	88.2256
SK-ES-1	GDSC2; CTRP2	-7.8887	-2.6444	-7.8979	87.6118
ES8	GDSC2	-7.87	-6.1294	-7.87	91.5255
NY	GDSC2	-7.3447	-4.2078	-7.3501	83.9798
TC-71	GDSC2	-7.1409	-5.6598	-7.1409	86.5665
SK-PN-DW	GDSC2	-7.1046	-4.5281	-7.106	83.7902
ES5	GDSC2	-7.0066	2.129	-7.9453	68.5966
SK-N-MC	CTRP2	-6.4509	-3.5016	-6.451	87.5326
EW-3	GDSC2	-6.3215	1.8588	-7.1199	66.585
EW-11	GDSC2	-6.1962	1.8457	-6.9795	66.1131
EW-22	GDSC2	-6.0167	1.1749	-6.6027	66.3511
EW-1	GDSC2	-5.8915	-3.0226	-5.9	73.2535
TC71	CTRP2	-5.5381	-3.9536	-5.5381	83.8308
EW-16	GDSC2	-5.3271	-3.4364	-5.3277	69.1212
SaOS-2	GDSC2; CTRP2	-5.291	0.6768	-5.3487	75.2279
EW-18	GDSC2	-4.7969	-0.3145	-4.9681	61.659
HOS	GDSC2; CTRP2	-4.2567	-0.4071	-4.2623	72.2144
HuO9	GDSC2	-4.1036	16.3504	-10.9459	51.8512
EW-7	GDSC2	-4.0767	1.124	-4.4743	55.3211
MHH-ES-1	GDSC2; CTRP2	-4.0763	-3.1131	-4.0763	72.0575
U2OS	GDSC2; CTRP2	-3.2677	4.8499	-3.6977	62.88
CADO-ES1	GDSC2; CTRP2	-1.5956	2.1894	-1.6186	55.8112
G-292 clone A141B1	GDSC2; CTRP2	-1.3005	4.5341	-1.5222	53.6119
CAL-72	GDSC2	-0.7752	6.925	-3.239	34.3739
CAL-78	GDSC2; CTRP2	0.3609	173.1757	-81.6688	49.6698
ES6	GDSC2	0.508	11.8883	-4.4896	33.1183
NOS-1 [Human HNSCC]	GDSC2	0.7774	7.6196	-2.1293	24.3661
ES4	GDSC2	1.2925	9.546	-2.6419	24.8581
EW-24	GDSC2	1.3157	17.7242	-6.7101	35.2199
SJSA-1	CTRP2	1.3736	13.9008	-1.7927	43.0065
Hs 888.T	CTRP2	1.4376	17.754	-3.4942	44.1455
H-EMC-SS	GDSC2	1.8582	10.9935	-2.8936	24.159
CHSA8926	GDSC2	2.9074	12.836	-2.98	21.695
HuO-3N1	GDSC2	3.3311	23.3721	-7.8898	32.7257
MG-63	GDSC2; CTRP2	3.6903	21.5155	-3.1591	37.7024
SW1353	CTRP2	3.8571	12.0024	1.5735	28.9524
EW-13	GDSC2	4.0764	19.5597	-5.42	26.4678
Hs 822.T	CTRP2	4.222	19.6362	-1.7473	35.1714

Cancer Drug Sensitivity Data Curated from 206 Cell Line(s) in Haematopoietic And Lymphoid Tissue Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
JK1	CTRP2	-8.8565	-1.2331	-8.9272	87.0454
MEC1	CTRP2	-4.4251	-3.7533	-4.4251	76.5584
JM1	CTRP2	-6.6334	-3.6531	-6.6335	88.3771
Ri-1	CTRP2	-12.1211	-0.1523	-12.4361	87.1996
EJM	GDSC2; CTRP2	-11.9405	-1.5519	-12.1088	88.7054
MOLM-6	CTRP2	-11.7435	-0.2694	-12.0231	87.2133
Mono-Mac-1	CTRP2	-11.661	2.685	-12.368	82.8784
CA46	GDSC2; CTRP2	-11.5631	3.7541	-12.4707	80.8338
KMS-28BM	CTRP2	-11.5083	11.626	-14.6219	73.3237
SUP-T11	CTRP2	-11.3023	11.4574	-14.3415	73.2501
Granta-519	GDSC2; CTRP2	-10.8304	1.2818	-11.2467	83.6468
MHH-CALL-4	CTRP2	-10.7574	-1.0256	-10.9146	87.9684
THP-1	CTRP2	-10.2917	-1.6318	-10.388	88.7846
MOTN-1	CTRP2	-10.1386	3.0438	-10.789	81.1308
NALM-6	GDSC2; CTRP2	-9.8083	-3.1529	-9.8316	90.5395
RCH-ACV	CTRP2	-9.7422	-5.3467	-9.7431	95.4613
SR	GDSC2; CTRP2	-9.5929	-2.0223	-9.6479	88.2661
TALL-1 [Human adult T-ALL]	CTRP2	-9.5698	7.8165	-11.3081	74.6495
SU-DHL-5	GDSC2	-9.5429	-8.0691	-9.5429	98.9051
U-937	CTRP2	-9.5421	-7.7343	-9.5421	99.2743
Pfeiffer	CTRP2	-9.5231	-5.931	-9.5232	96.4994
BV-173	CTRP2	-9.484	-6.6071	-9.484	97.6676
Hs 611.T	CTRP2	-9.3822	-0.074	-9.555	85.3868
OCI-Ly3	CTRP2	-9.3423	-6.9457	-9.3423	98.2335
OCI-Ly19	CTRP2	-9.2818	-6.01	-9.2819	96.6249
ATN-1	GDSC2	-9.2462	-4.5448	-9.2732	89.1614
Daudi	GDSC2; CTRP2	-9.2323	-2.8956	-9.2528	89.651
HH [Human lymphoma]	GDSC2; CTRP2	-9.2252	-0.4736	-9.3578	85.1076
OCI-Ly10	CTRP2	-9.2162	-2.3383	-9.251	89.4677
EB1	CTRP2	-9.1879	-2.4061	-9.2201	89.5801
HPB-ALL	CTRP2	-9.1735	-5.628	-9.1737	95.896
697	GDSC2; CTRP2	-9.1588	-7.876	-9.1588	99.1136
BE-13	GDSC2	-9.0715	-2.4742	-9.2394	83.239
MOLM-16	CTRP2	-9.0643	-3.6746	-9.0713	92.0102
MOLT-3	CTRP2	-9.0195	-7.999	-9.0195	99.7159
NU-DUL-1	CTRP2	-9.0041	-7.2031	-9.0041	98.6908
P32/ISH	GDSC2	-8.961	-6.9439	-8.961	96.0758
SEM	CTRP2	-8.6664	-4.5795	-8.6672	93.6001
L-540	GDSC2; CTRP2	-8.5203	-2.4112	-8.541	88.0044
WSU-NHL	GDSC2	-8.4552	-5.532	-8.4566	91.1246
ARH-77	GDSC2	-8.3761	-2.6872	-8.4843	82.5191
KMS-11	CTRP2	-8.3543	-4.0852	-8.3557	92.3388
EoL-1	GDSC2; CTRP2	-8.2964	-6.9618	-8.2964	96.9856
KY821	GDSC2	-8.1953	-5.3897	-8.1965	90.1635
SUP-M2	GDSC2; CTRP2	-8.1568	-1.3724	-8.2017	85.513
BALL-1	GDSC2	-8.1568	-6.5347	-8.1568	93.6602
KMS-12-BM	GDSC2; CTRP2	-8.1548	-4.3043	-8.1554	91.3608
MOLT-16	GDSC2; CTRP2	-8.1491	-6.6974	-8.1491	96.2118
GA-10	GDSC2; CTRP2	-8.131	-7.0965	-8.131	96.967
CTV-1	GDSC2	-8.0834	-4.3118	-8.0956	86.569
AML-193	CTRP2	-8.0021	8.0996	-9.6806	72.2027
RS4;11	GDSC2; CTRP2	-7.977	-1.7991	-8.004	86.0793
MJ	CTRP2	-7.9048	3.1543	-8.3984	78.2739
DB	GDSC2; CTRP2	-7.841	-4.7515	-7.8411	91.7558
Ramos.2G6.4C10	GDSC2	-7.718	-6.7539	-7.718	92.4764
KMS-34	CTRP2	-7.7082	-5.6956	-7.7082	94.9668
JVM-3	GDSC2; CTRP2	-7.5808	-5.8355	-7.5808	93.2038
SU-DHL-6	GDSC2; CTRP2	-7.5752	-6.5715	-7.5752	94.3046
Farage	GDSC2	-7.5423	-2.4583	-7.6301	79.7687
Loucy	GDSC2	-7.5299	-4.1937	-7.5374	84.6208
CCRF-CEM	GDSC2	-7.4868	-6.7053	-7.4868	90.7571
SU-DHL-10	GDSC2	-7.4609	-6.5525	-7.4609	90.3497
SU-DHL-4	CTRP2	-7.4445	-5.3482	-7.4445	93.7488
MLMA	GDSC2	-7.4367	-6.3119	-7.4367	89.7782
ST486	GDSC2; CTRP2	-7.4245	-4.0385	-7.4247	89.4905
DEL	GDSC2; CTRP2	-7.3803	-3.371	-7.3817	88.1084
RPMI-8866	GDSC2	-7.3448	-4.2727	-7.3495	84.1636
SUP-B15	GDSC2; CTRP2	-7.337	-3.1332	-7.3391	87.5548
RPMI-6666	GDSC2; CTRP2	-7.3189	-4.2259	-7.319	89.5863
OPM-2	GDSC2; CTRP2	-7.315	-4.496	-7.315	90.0711
U-698-M	GDSC2	-7.3041	-6.4132	-7.3041	88.9256
Karpas-231	GDSC2	-7.2907	-3.8293	-7.3019	82.7058
Namalwa	GDSC2; CTRP2	-7.254	-2.8034	-7.2575	86.7388
TUR	GDSC2	-7.2409	-6.3663	-7.2409	88.3466
SCC-3	GDSC2	-7.2367	-6.4779	-7.2367	88.4021
KMS-21-BM	CTRP2	-7.2305	-5.9946	-7.2305	94.368
MHH-CALL-2	GDSC2	-7.2211	0.8215	-7.8282	71.4379
MOLP-2	CTRP2	-7.2092	0.022	-7.2952	82.4909
MOLP-8	GDSC2; CTRP2	-7.1561	0.0624	-7.2427	81.1572
NCO2	CTRP2	-7.1544	-5.1257	-7.1544	92.5964
CML-T1	GDSC2; CTRP2	-7.1522	-1.5579	-7.1715	84.1431
MOLM-13	GDSC2; CTRP2	-7.1486	-1.3887	-7.1721	83.8163
ML-2	GDSC2	-7.1389	-5.9076	-7.1389	86.9621
SU-DHL-8	GDSC2; CTRP2	-7.0732	-4.909	-7.0732	90.0104
Mino	CTRP2	-7.0553	-3.7298	-7.0556	89.6423
AMO1	GDSC2; CTRP2	-7.055	-4.9731	-7.055	90.0392
BC-1	GDSC2	-7.0455	-5.5903	-7.0455	85.776
Karpas-45	GDSC2	-7.0367	-2.7256	-7.0845	78.7215
JJN-3	GDSC2; CTRP2	-7.0148	-4.8605	-7.0148	89.7233
OCI-AML-3	GDSC2; CTRP2	-6.908	-5.8451	-6.908	90.2965
ALL-PO	GDSC2	-6.904	-3.6523	-6.9135	80.5728
MHH-PREB-1	GDSC2	-6.8865	3.3705	-8.2028	66.5072
F-36P	CTRP2	-6.8751	-3.6315	-6.8753	92.4126
ALL-SIL	GDSC2; CTRP2	-6.8396	-4.5953	-6.8396	88.6728
DG-75	GDSC2	-6.832	0.3886	-7.3038	70.9201
KE-37	GDSC2; CTRP2	-6.8279	-6.0111	-6.8279	89.886
H9	GDSC2	-6.8204	-4.3417	-6.8217	81.8204
EB2	GDSC2	-6.7842	2.3138	-7.7575	67.5942
SKM-1	GDSC2; CTRP2	-6.7717	-5.0986	-6.7717	88.9932
KHM-1B	CTRP2	-6.7609	-5.206	-6.7609	91.3506
Jiyoye	GDSC2	-6.7556	-2.2041	-6.8282	76.2493
Kasumi-1	GDSC2	-6.7188	-2.7701	-6.7539	77.4794
KYO-1	CTRP2	-6.6047	1.884	-6.8253	78.0286
P30/OHK	GDSC2	-6.5997	5.9787	-8.8392	62.8843
IM-9	GDSC2	-6.5619	-5.3009	-6.5619	81.5172
KMS-27	CTRP2	-6.5103	-5.9677	-6.5103	90.4989
Hs 445	GDSC2	-6.3897	3.7054	-7.7772	64.4671
A3/Kawakami	GDSC2; CTRP2	-6.3839	-5.3468	-6.3839	86.9957
JSC-1	GDSC2	-6.3792	-3.4129	-6.3866	77.1853
JURL-MK1	GDSC2; CTRP2	-6.362	-3.7148	-6.362	85.5549
HC-1	GDSC2	-6.3617	-4.4993	-6.3618	78.9941
Peer	CTRP2	-6.3564	-4.7688	-6.3564	88.9562
RL	CTRP2	-6.3069	5.3939	-7.1141	72.2754
P12-Ichikawa	GDSC2; CTRP2	-6.2828	-5.5673	-6.2828	86.3804
KMS-26	CTRP2	-6.2331	-5.5059	-6.2331	88.6373
MV4-11	CTRP2	-6.2282	3.8492	-6.712	74.1832
NU-DHL-1	CTRP2	-6.2061	-1.5463	-6.2144	86.6215
KE-97	CTRP2	-6.1973	-4.6688	-6.1973	88.0408
BL-70	CTRP2	-6.1308	-2.2284	-6.1329	84.2941
TK [Human B-cell lymphoma]	GDSC2	-6.1229	3.622	-7.4598	63.6104
LC4-1	GDSC2	-6.0726	-1.0777	-6.224	70.5622
KOPN-8	GDSC2	-6.0712	-4.26	-6.0714	76.3437
Karpas-422	GDSC2; CTRP2	-6.0684	-2.6312	-6.0691	82.9066
MC116	CTRP2	-6.0364	-4.5705	-6.0364	87.081
JeKo-1	CTRP2	-5.9544	-4.6308	-5.9544	86.6378
MEG-01	GDSC2	-5.9203	-2.4758	-5.9463	72.4709
HD-MY-Z	CTRP2	-5.8953	10.0869	-8.0168	66.612
RPMI-8402	CTRP2	-5.8803	-4.3914	-5.8803	86.0762
VL51	GDSC2	-5.7957	-1.4628	-5.887	69.8042
Kasumi-2	CTRP2	-5.7101	-3.5316	-5.7101	89.3496
NB4	CTRP2	-5.6845	-4.4329	-5.6845	84.908
Ci-1	CTRP2	-5.6581	-4.6568	-5.6581	84.784
KMS-18	CTRP2	-5.637	-1.5073	-5.6415	81.4274
CESS	GDSC2	-5.5674	-3.8497	-5.5676	71.564
L-363	GDSC2; CTRP2	-5.5471	-4.4535	-5.5471	81.5962
HT	CTRP2	-5.5235	-3.803	-5.5235	83.6681
VAL	GDSC2	-5.5211	-0.7994	-5.6731	67.0276
DND-41	GDSC2; CTRP2	-5.5162	4.4248	-6.0497	70.6782
WIL2 NS	GDSC2	-5.5035	-3.5362	-5.5042	70.7824
SU-DHL-1	CTRP2	-5.4868	-0.979	-5.496	80.0486
Ku812	GDSC2; CTRP2	-5.4388	-2.2892	-5.4393	79.7803
P31/FUJ	CTRP2	-5.438	-3.9722	-5.438	83.2274
M-07e	CTRP2	-5.4235	-3.1446	-5.4235	87.5518
GR-ST	GDSC2	-5.3178	9.2502	-8.8598	56.8762
L-1236	GDSC2	-5.317	3.17	-6.433	60.7956
PL21	CTRP2	-5.2894	-3.732	-5.2894	82.2261
Reh	GDSC2; CTRP2	-5.2695	-4.2769	-5.2695	79.8016
SUP-T1	GDSC2; CTRP2	-5.2205	3.6451	-5.5912	70.8576
SUP-HD1	GDSC2; CTRP2	-5.2163	2.7824	-5.4603	71.9881
OCI-AML-5	GDSC2; CTRP2	-5.1931	-4.5344	-5.1931	79.309
MM1.S	GDSC2; CTRP2	-5.1589	-2.1822	-5.1593	78.3076
HuT 78	CTRP2	-5.1445	3.0849	-5.4247	72.5837
Karpas-1106P	GDSC2	-5.1381	4.8174	-6.8327	58.6605
EM-2	GDSC2; CTRP2	-5.0757	-2.0111	-5.0762	77.7384
RPMI-8226	GDSC2; CTRP2	-5.0374	-3.3017	-5.0374	78.2241
L-428	GDSC2; CTRP2	-4.9934	5.3911	-5.6841	68.1323
WSU-DLCL2	CTRP2	-4.7635	-4.0851	-4.7635	78.822
RC-K8	GDSC2	-4.6972	-0.4215	-4.8456	61.0601
KMS-20	CTRP2	-4.5874	-0.7559	-4.5918	80.2516
A4/Fukuda	GDSC2; CTRP2	-4.5697	-3.7079	-4.5697	75.2614
NCI-H929	GDSC2; CTRP2	-4.5591	-1.422	-4.56	74.5784
KO52	CTRP2	-4.525	-3.9542	-4.525	77.2269
HL-60	GDSC2; CTRP2	-4.5191	-3.8903	-4.5191	74.9328
SIG-M5	CTRP2	-4.5142	-4.07	-4.5142	77.1547
OCI-M1	GDSC2; CTRP2	-4.4049	-3.4886	-4.4049	74.1913
HuNS1	CTRP2	-4.3996	-3.5885	-4.3996	76.3882
HDLM-2	GDSC2; CTRP2	-4.3532	1.5473	-4.4298	70.5929
U266B1	GDSC2; CTRP2	-4.2948	17.6872	-9.2761	58.5343
BCP-1	CTRP2	-4.2705	-0.8406	-4.2728	74.5765
DoHH2	GDSC2; CTRP2	-4.2466	-3.2594	-4.2466	73.1636
SET-2	CTRP2	-4.2361	-1.3994	-4.2365	74.8161
MOLT-13	GDSC2; CTRP2	-4.2097	-2.6016	-4.2097	72.9082
PF-382	GDSC2; CTRP2	-4.0488	0.0585	-4.0588	70.771
Karpas-299	GDSC2; CTRP2	-4.0405	-1.5864	-4.0406	71.6784
Ki-JK	CTRP2	-3.9897	-0.3928	-3.9936	72.7158
JVM-2	GDSC2; CTRP2	-3.916	-0.902	-3.924	63.8101
K-562	GDSC2; CTRP2	-3.751	-2.0081	-3.751	69.9306
OCI-AML-2	GDSC2; CTRP2	-3.7403	-3.2866	-3.7403	69.8761
HAL-01	GDSC2	-3.7056	-2.0624	-3.7069	53.0835
Mono-Mac-6	CTRP2	-3.5263	27.4229	-12.9025	55.3089
Raji	GDSC2; CTRP2	-3.5019	-1.4243	-3.5019	68.2933
LP-1	GDSC2; CTRP2	-3.2798	1.4921	-3.3173	65.7224
MN-60	GDSC2	-3.0652	5.4758	-4.9034	48.1148
SK-MM-2	GDSC2; CTRP2	-2.7141	1.1091	-2.7269	62.8284
KMOE-2	GDSC2	-2.6826	5.3164	-4.4374	45.7449
Jurkat	GDSC2; CTRP2	-2.6678	-1.676	-2.6678	54.1827
NOMO-1	GDSC2; CTRP2	-2.5918	5.4057	-3.0767	59.6618
TF-1	CTRP2	-2.4723	3.0758	-2.5872	62.0468
EHEB	CTRP2	-2.4562	3.725	-2.6434	61.515
KCL-22	GDSC2; CTRP2	-2.4185	-1.1464	-2.4185	61.2948
HEL 92.1.7	CTRP2	-2.3849	0.0142	-2.3853	62.8702
KM-H2	GDSC2; CTRP2	-2.2598	-1.3662	-2.2598	60.2642
ME1	GDSC2	-1.9763	4.3033	-3.275	40.0885
KG-1	GDSC2	-1.941	2.5855	-2.5763	37.9273
LAMA-84	GDSC2; CTRP2	-1.9121	1.6647	-1.9255	57.8535
GDM-1	GDSC2; CTRP2	-1.1525	4.6669	-1.384	52.7555
HEL	GDSC2; CTRP2	-0.7374	0.8723	-0.7379	43.0707
MHH-CALL-3	CTRP2	-0.3833	22.4267	-7.4746	49.8369
P3HR-1	CTRP2	-0.375	74.9985	-33.3114	49.9427
MOLT-4	GDSC2	-0.3078	4.2931	-1.5501	25.6983
ME1	CTRP2	1.3531	9.1763	0.1376	40.6309
Toledo	CTRP2	6.3237	22.7424	-1.4272	30.1135
Karpas-620	GDSC2; CTRP2	8.1957	12.161	5.353	4.9199
REC-1	CTRP2	8.5951	14.6695	4.417	8.2479
BL-41	GDSC2; CTRP2	8.9077	32.3048	-4.0841	29.6273
KMM-1	CTRP2	8.9095	12.2447	5.7657	2.5726

Cancer Drug Sensitivity Data Curated from 27 Cell Line(s) in Oesophagus Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
TE15	CTRP2	-9.6436	35.2469	-22.591	60.9433
TE8	CTRP2	-9.1618	18.2515	-14.6022	66.3409
TE-15	GDSC2	-5.9987	-2.2157	-6.0403	72.4463
EC-GI-10	GDSC2; CTRP2	-5.1024	12.9071	-8.1796	62.3384
TE-11	CTRP2	-4.3235	-3.1096	-4.3235	75.8737
TE-8	GDSC2	-4.2486	2.7302	-5.1273	55.5767
OE21	GDSC2; CTRP2	-3.8545	8.4795	-5.2756	62.0672
TE-5	GDSC2; CTRP2	-3.8373	33.3727	-16.0208	54.5713
TE-4	GDSC2; CTRP2	-3.6448	9.275	-5.3038	60.916
KYSE-410	GDSC2; CTRP2	-2.7383	17.1577	-7.4392	55.347
TE-6	GDSC2; CTRP2	-2.6078	13.2766	-5.672	56.0766
TE-9	GDSC2; CTRP2	-2.2926	28.0824	-12.0091	52.8421
KYSE-180	GDSC2; CTRP2	-2.0884	0.2685	-2.0888	59.133
TE-14	CTRP2	-0.6377	12.1779	-3.148	52.5886
KYSE-510	GDSC2; CTRP2	0.0264	382.6089	-186.6322	49.8988
OE19	GDSC2; CTRP2	0.7328	9.3934	-0.609	43.1423
TE-10	CTRP2	1.0618	6.6573	0.6133	40.9376
KYSE-150	CTRP2	2.4164	19.874	-3.5543	43.005
KYSE-270	GDSC2	3.0669	11.778	-2.3354	18.6746
KYSE-70	GDSC2; CTRP2	4.0181	8.9207	3.0834	22.7991
KYSE-450	GDSC2; CTRP2	4.2469	21.8454	-2.8126	36.0607
OE33	GDSC2; CTRP2	4.4062	13.0265	1.6348	26.5786
KYSE-140	GDSC2; CTRP2	5.8825	21.8656	-1.3693	30.3612
KYSE-520	GDSC2; CTRP2	6.3838	23.4659	-1.7374	30.0604
TE-1	GDSC2; CTRP2	7.0066	17.9901	1.5254	21.086
KYSE-30	CTRP2	8.3936	23.8398	-0.2728	24.8336
COLO 680N	GDSC2; CTRP2	10.3552	28.837	-1.2473	22.5077

Cancer Drug Sensitivity Data Curated from 39 Cell Line(s) in Pancreas Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
N2a-PK1	CTRP2	3.0951	8.8063	2.1447	29.4837
KP-4	GDSC2; CTRP2	-7.8453	16.2495	-12.4043	65.2198
MIA PaCa-2	GDSC2; CTRP2	-7.1217	9.2441	-9.0727	68.9703
PSN1	GDSC2; CTRP2	-3.7345	8.004	-4.999	62.0442
BxPC-3	GDSC2; CTRP2	-2.4703	5.5705	-2.98	59.033
PaTu 8988t	GDSC2; CTRP2	-2.4009	5.0931	-2.8064	58.9979
HuP-T4	GDSC2; CTRP2	-0.6965	29.9298	-11.3632	50.0309
PL4	GDSC2	-0.3086	7.3541	-2.9976	31.7348
Panc 03.27	CTRP2	-0.123	25.3367	-8.6062	49.3098
L3.3	CTRP2	0.4415	10.1947	-1.2203	45.8935
QGP-1	GDSC2; CTRP2	1.5931	21.9878	-5.3566	44.2335
KP-1N	GDSC2	1.8332	9.2335	-2.0344	20.6135
KP-2	GDSC2; CTRP2	3.1762	21.052	-3.4087	39.1293
SW1990	CTRP2	3.3834	23.0887	-4.2139	40.0109
Panc 08.13	GDSC2; CTRP2	3.4751	25.0503	-5.0952	40.0623
Hs 766T	CTRP2	3.963	14.6599	0.4283	33.2759
KP-3	GDSC2; CTRP2	4.2154	15.5468	0.2426	30.7537
SU.86.86	GDSC2; CTRP2	4.2321	22.1145	-2.9589	36.2827
HuP-T3	GDSC2; CTRP2	4.4644	20.5003	-1.9514	34.3491
DAN-G	GDSC2; CTRP2	4.8119	25.0011	-3.8696	36.2227
YAPC	GDSC2; CTRP2	4.9278	11.7291	2.7566	21.5874
PK-45H	CTRP2	5.1542	17.5023	0.1542	29.3201
Capan-1	GDSC2; CTRP2	5.1678	20.1669	-1.153	31.4414
AsPC-1	GDSC2; CTRP2	6.5074	17.7762	1.2104	23.0154
PK-59	CTRP2	6.6423	16.7883	1.8191	21.4147
PaTu 8988s	CTRP2	6.9343	65.6902	-22.385	43.1799
Capan-2	GDSC2; CTRP2	6.9592	20.0637	0.449	24.1952
SNU-213	CTRP2	7.203	16.0201	2.6731	17.394
Panc 05.04	CTRP2	7.4322	9.4774	6.1174	3.0869
Panc 04.03	CTRP2	7.5261	19.4918	1.2023	21.5279
Panc 10.05	GDSC2; CTRP2	7.6634	28.117	-2.9957	29.9234
CFPAC-1	GDSC2; CTRP2	7.8746	13.5087	4.4592	8.9725
SNU-410	CTRP2	8.6085	12.5461	5.444	4.1396
SUIT-2	GDSC2; CTRP2	9.0404	10.2929	6.6191	0.1058
TCC-Pan2	CTRP2	9.8016	19.4492	2.945	11.9701
PaTu 8902	GDSC2; CTRP2	10.2492	18.7707	3.5706	8.8915
HPAC	GDSC2; CTRP2	10.3148	22.0229	2.0571	13.8966
Panc 02.03	GDSC2; CTRP2	10.7533	24.4307	1.1974	15.8628
HPAF-II	GDSC2; CTRP2	12.7271	28.4772	0.5956	14.9439

Cancer Drug Sensitivity Data Curated from 62 Cell Line(s) in Skin Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
SH4	CTRP2	7.9266	23.8611	-1.3481	24.1487
MDA-MB-435S	CTRP2	-8.9716	25.2885	-17.401	63.0946
Hs 294T	CTRP2	-7.8644	13.9567	-11.5319	67.1319
CHL-1	GDSC2	-7.2725	8.2428	-10.46	62.8912
WM88	CTRP2	-6.1686	15.0483	-10.1494	63.7522
IGR-1	GDSC2; CTRP2	-6.0244	23.8391	-13.7529	59.4652
G-mel	GDSC2	-6.0081	1.9128	-6.7934	65.2541
RPMI-7951	GDSC2; CTRP2	-5.922	-0.3417	-5.9529	78.8321
LOX-IMVI	GDSC2; CTRP2	-5.8564	11.701	-8.5399	64.6423
RVH-421	CTRP2	-5.1777	3.5536	-5.5305	72.0178
IGR-37	GDSC2; CTRP2	-5.0303	-2.5024	-5.0304	77.8564
MeWo	CTRP2	-4.7925	21.6937	-11.5419	58.6356
Hs 944.T	CTRP2	-4.6052	46.2354	-22.954	54.4351
CJM [Human melanoma]	CTRP2	-4.4827	-3.6117	-4.4827	76.9432
A2058	GDSC2; CTRP2	-4.4037	-2.317	-4.4037	74.0903
HMCB	CTRP2	-4.2672	12.5084	-7.135	61.3881
SK-MEL-5	GDSC2; CTRP2	-3.5885	11.7967	-6.1391	59.3533
HMV-II	GDSC2	-2.6001	5.0174	-4.2254	45.084
COLO 741	CTRP2	-2.2505	15.1379	-6.0667	55.2698
M14	GDSC2	-2.0941	19.9725	-10.8299	46.8244
WM1552C	GDSC2	-1.9887	4.9874	-3.5766	40.8203
G-361	GDSC2; CTRP2	-1.8049	2.4031	-1.8427	57.0393
Mel Ho	CTRP2	-1.7	8.2217	-2.8493	55.642
WM983B	CTRP2	-1.6694	25.5056	-10.1828	52.383
GAK	GDSC2	-1.2411	4.709	-2.685	34.6793
Hs 852.T	CTRP2	0.0516	7.9157	-0.8465	47.2762
A-375	GDSC2; CTRP2	0.0919	11.568	-2.1313	46.8637
HT-144	GDSC2; CTRP2	0.2723	16.9359	-4.2745	47.1118
Hs 936.T	CTRP2	0.3255	57.3916	-23.9399	49.238
COLO 679	GDSC2	0.6146	10.1496	-3.5307	30.1639
SH-4	GDSC2	0.8894	11.7774	-4.1019	30.9569
WM1799	CTRP2	1.3582	9.5632	-0.0004	40.8408
COLO 800	CTRP2	1.3871	17.7954	-3.5631	44.3273
WM278	GDSC2	2.7463	7.397	-0.4193	9.5749
CP66-MEL	GDSC2	2.85	16.092	-4.6431	27.183
Mel JuSo	GDSC2; CTRP2	3.1038	17.4823	-1.7481	37.2699
WM35	GDSC2	3.4091	18.3441	-5.3272	27.6521
K029AX	CTRP2	4.0498	47.1985	-15.5936	44.3586
COLO 792	GDSC2; CTRP2	4.2165	17.0299	-0.4766	32.3054
WM793	GDSC2; CTRP2	4.4569	15.2266	0.6257	29.2254
SK-MEL-3	CTRP2	4.8203	26.089	-4.4029	37.2886
Hs 934.T	CTRP2	4.8317	19.2357	-0.9939	32.4739
Malme-3M	CTRP2	4.9229	7.3435	4.636	15.0625
A101D	GDSC2; CTRP2	5.0136	16.5112	0.515	28.1609
SK-MEL-2	GDSC2; CTRP2	5.7291	13.0323	2.8817	19.2546
Hs 940.T	CTRP2	6.7926	21.4309	-0.3743	27.0203
COLO 829	GDSC2; CTRP2	6.8348	42.1655	-10.7058	38.7297
Hs 688(A).T	CTRP2	7.1649	12.3087	4.497	10.3583
IPC-298	CTRP2	7.5734	20.637	0.6687	22.9334
SK-MEL-24	GDSC2; CTRP2	7.7843	15.5425	3.3795	13.3152
WM115	GDSC2; CTRP2	7.9674	40.9305	-9.1507	36.2549
IGR-39	CTRP2	8.1067	23.7806	-0.4712	24.791
SK-MEL-28	CTRP2	8.2911	18.2037	2.4507	16.1511
Hs 895.T	CTRP2	8.2925	20.5933	1.2642	19.9352
SK-MEL-1	CTRP2	8.744	23.715	0.0638	22.4094
Hs 839.T	CTRP2	9.5735	25.5307	-0.2013	21.7041
SK-MEL-30	CTRP2	9.7178	19.5697	2.8283	12.5267
SK-MEL-31	CTRP2	11.5808	25.0671	1.4579	14.303
UACC-257	GDSC2; CTRP2	12.04	26.0701	1.2855	13.9084
WT2-iPS	GDSC2; CTRP2	12.4755	42.7793	-6.5399	28.2655
WM266-4	CTRP2	14.7426	52.1346	-9.4678	29.3234
UACC-62	GDSC2; CTRP2	16.4062	41.5137	-3.17	19.0197

Cancer Drug Sensitivity Data Curated from 10 Cell Line(s) in Aero Dig Tract Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
FLO-1	GDSC2	-6.8036	-3.6988	-6.811	80.1979
OACM5.1 C	GDSC2	-5.3841	5.8572	-7.5	58.9173
OACP4 C	GDSC2	-2.7253	7.111	-5.2652	46.5953
KYSE-220	GDSC2	-2.3862	7.4156	-5.0604	44.8727
TE-12	GDSC2	-1.444	6.7884	-3.8313	38.7667
SK-GT-4	GDSC2	-0.8958	18.9392	-9.2373	43.2822
ESO-51	GDSC2	-0.3327	4.0242	-1.4541	25.3151
ESO-26	GDSC2	-0.2444	99.3753	-48.843	48.2638
KYSE-50	GDSC2	1.3967	15.3616	-5.4609	32.7529
KYAE-1	GDSC2	4.3486	6.2907	0.9531	0.3807

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Ascites Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
COLO 684	GDSC2; CTRP2	-5.6925	7.2282	-6.9105	67.9821

Cancer Drug Sensitivity Data Curated from 28 Cell Line(s) in Autonomic Ganglia Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
CHP-126	CTRP2	-8.9469	5.4084	-9.9927	76.6179
IMR-5	GDSC2	-7.5694	-4.3406	-7.5752	85.1859
SJNB-13	GDSC2	-6.7077	-4.0017	-6.7106	80.4038
SJNB-14	GDSC2	-6.425	-2.7682	-6.4518	76.02
MHH-NB-11	CTRP2	-6.2106	-3.8028	-6.2106	87.1136
NB69	GDSC2	-5.4895	-3.7954	-5.4897	70.8141
TGW	GDSC2	-4.6281	-2.251	-4.635	62.05
NB1	CTRP2	-4.6234	-2.8181	-4.6234	77.7876
CHP-212	GDSC2; CTRP2	-4.5219	-2.3907	-4.5219	74.8343
SK-N-AS	GDSC2; CTRP2	-4.3952	14.5311	-8.0658	59.9931
IMR-32	CTRP2	-4.3946	-3.985	-4.3946	76.3546
SK-N-DZ	GDSC2; CTRP2	-4.0973	2.0196	-4.198	69.0083
SJNB-10	GDSC2	-3.8746	-2.0051	-3.8774	54.7588
Kelly	GDSC2; CTRP2	-3.4908	-0.8091	-3.4912	68.115
SK-N-BE(2)	CTRP2	-3.3637	8.5168	-4.753	61.4757
NH-6	CTRP2	-3.2569	8.4732	-4.623	61.1688
SK-N-FI	CTRP2	-2.908	0.4147	-2.9122	66.0679
SK-N-BE(2)-M17	GDSC2	-2.8397	0.8456	-3.0639	44.9565
NB(TU)1	GDSC2	-2.6437	0.9493	-2.8732	43.1427
SiMa	GDSC2; CTRP2	-2.597	1.9525	-2.6364	61.7829
SK-N-SH	CTRP2	-2.3553	3.1115	-2.4675	61.4134
KP-N-SI9s	CTRP2	-2.3474	1.2148	-2.3574	62.3557
CHP-134	GDSC2	-2.0026	9.6337	-5.7153	43.8899
NH-12	GDSC2	-1.7805	6.7392	-4.1441	40.8956
GOTO	GDSC2	-0.4846	9.9159	-4.4099	36.2274
SJNB-7	GDSC2	0.6214	7.9363	-2.4256	26.1753
GI-ME-N	GDSC2	3.1	16.1058	-4.4547	26.0765
KP-N-YN	GDSC2; CTRP2	9.2568	20.4622	2.0615	15.4589

Cancer Drug Sensitivity Data Curated from 8 Cell Line(s) in Biliary Tract Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
SNU-478	CTRP2	-8.4891	11.1345	-11.1837	70.126
SNU-308	CTRP2	2.9923	14.4826	-0.4338	36.1692
SNU-245	CTRP2	4.0499	15.5541	0.0821	32.2193
HuH-28	CTRP2	4.4034	13.3939	1.4572	27.7921
HuCC-T1	GDSC2; CTRP2	5.046	20.4284	-1.3914	32.1415
SNU-1196	CTRP2	5.1984	15.31	1.2751	26.3069
SNU-1079	CTRP2	5.9453	17.6836	0.7695	25.9815
SNU-869	CTRP2	7.3757	27.9796	-3.1633	31.1012

Cancer Drug Sensitivity Data Curated from 63 Cell Line(s) in Breast Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
MDA-MB-468	GDSC2; CTRP2	-11.7399	31.6467	-23.0518	63.491
HCC1806	GDSC2; CTRP2	-10.179	28.9007	-20.2371	62.858
HCC2157	GDSC2	-6.8435	-4.8906	-6.8436	83.1236
HCC1187	GDSC2	-6.8383	7.687	-9.7751	62.19
MRK-nu-1	GDSC2	-6.8274	3.8308	-8.2942	65.7616
SK-BR-3	CTRP2	-6.7417	21.079	-13.2683	62.7732
AU565	GDSC2; CTRP2	-6.3279	27.4455	-15.6932	58.9063
MDA-MB-330	GDSC2	-5.9662	-1.8873	-6.0287	71.6044
Hs 578T	GDSC2; CTRP2	-5.591	2.194	-5.787	73.9087
MDA-MB-157	GDSC2; CTRP2	-5.5436	9.7544	-7.524	65.4124
OCUB-M	GDSC2	-4.7577	-0.0514	-4.9687	61.098
HCC1954	GDSC2; CTRP2	-4.345	92.8787	-45.7117	52.065
CAL-148	CTRP2	-4.1341	-3.1447	-4.1341	74.6118
DU4475	GDSC2; CTRP2	-3.9942	1.1411	-4.0357	69.4985
CAL-51	GDSC2; CTRP2	-3.8028	4.2414	-4.1649	65.5
EFM-19	GDSC2	-3.4767	8.3306	-6.5745	50.3439
HCC1500	GDSC2; CTRP2	-3.19	3.3348	-3.3748	63.8173
HMC-1-8	CTRP2	-2.6898	-1.5551	-2.6898	64.9535
MFM-223	GDSC2	-2.426	5.9009	-4.4237	44.3991
JIMT-1	GDSC2; CTRP2	-2.1263	3.1014	-2.2259	58.6475
MDA-MB-453	GDSC2; CTRP2	-0.8609	58.9635	-25.7787	50.166
HCC38	GDSC2; CTRP2	-0.5315	42.9554	-17.5715	49.8162
MDA-MB-436	GDSC2	-0.4685	10.9656	-4.9101	37.1843
HCC1569	GDSC2; CTRP2	-0.4406	13.3225	-3.4142	49.1534
Evsa-T	GDSC2	-0.2747	18.4998	-8.4681	41.2033
MDA-MB-361	GDSC2; CTRP2	0.2365	12.4651	-2.3475	46.4441
HCC1395	CTRP2	0.4594	7.2721	-0.2098	44.909
MCF-7	GDSC2; CTRP2	1.1217	17.6227	-3.7443	44.5021
COLO 824	GDSC2	1.3671	16.0328	-5.8213	33.5461
CAL-85-1	GDSC2	1.418	16.7405	-6.1324	33.994
HCC2218	CTRP2	1.5682	11.0509	-0.3653	42.7091
UACC-812	CTRP2	2.8415	17.5022	-2.0091	38.967
HCC70	GDSC2	2.9612	21.0789	-7.0402	32.093
BT-549	GDSC2; CTRP2	3.5665	30.4088	-7.6625	41.6649
HCC202	CTRP2	4.6413	18.5478	-0.8278	32.604
Hs 578Bst	CTRP2	5.0036	24.7127	-3.5568	35.9775
CAMA-1	GDSC2; CTRP2	5.1	22.2679	-2.2563	33.4699
HCC1419	GDSC2; CTRP2	5.7006	20.0045	-0.6006	29.2043
ZR-75-1	CTRP2	5.7443	17.9762	0.447	27.2161
BT-474	GDSC2; CTRP2	5.8306	26.87	-3.9113	34.3775
ZR-75-30	GDSC2; CTRP2	5.9606	22.2805	-1.5086	30.4642
EFM-192A	GDSC2; CTRP2	6.9417	22.5974	-0.8325	27.2323
KPL-1	CTRP2	7.7354	12.5814	4.8125	8.0192
HCC1937	GDSC2; CTRP2	7.9288	11.8973	5.2928	5.5496
CAL-120	GDSC2; CTRP2	8.1779	18.8038	2.0648	17.2291
BT-20	GDSC2; CTRP2	8.3164	31.9634	-4.3868	30.9261
T-47D	GDSC2; CTRP2	9.6426	22.8796	1.1574	17.607
MDA-MB-231	GDSC2; CTRP2	9.7221	28.3639	-1.4905	23.9473
MDA-MB-415	GDSC2; CTRP2	10.6734	39.0453	-6.0574	29.8299
HDQ-P1	GDSC2; CTRP2	11.0274	33.8522	-3.2186	25.3095
HCC1143	GDSC2; CTRP2	11.8689	28.3926	0.057	17.4034
HCC1428	GDSC2; CTRP2	12.587	29.2041	0.1561	16.2436
BT 145	CTRP2	-9.7889	5.7529	-10.9939	77.2191
BT 239	CTRP2	-3.4691	1.9114	-3.5357	71.5458
BT 179	CTRP2	-1.5233	57.6068	-25.7024	50.9869
BT164	CTRP2	-1.3248	32.9739	-13.4302	51.3684
BT 231	CTRP2	-1.0172	31.1476	-12.2556	51.7666
BT 112	CTRP2	-0.3617	77.4492	-34.5193	49.9352
BT 228	CTRP2	2.4553	14.8759	-1.1479	40.587
BT 248	CTRP2	3.2686	22.8627	-4.2087	40.2544
BT 224	CTRP2	4.4378	26.1439	-4.7694	38.3856
BT 159	CTRP2	9.4378	30.9907	-3.0132	28.4495
BT 139	CTRP2	9.5735	28.2208	-1.5331	25.5552

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Tongue Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
YD-38	CTRP2	-2.6899	4.038	-2.9364	62.3947

Cancer Drug Sensitivity Data Curated from 55 Cell Line(s) in Central Nervous System Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
Hs 683	CTRP2	-12.1417	16.7951	-17.1861	70.3853
Becker	GDSC2; CTRP2	-8.5543	6.2675	-9.7768	74.3529
SF539	GDSC2; CTRP2	-8.476	1.0043	-8.7074	81.6538
H4	GDSC2	-5.8278	-2.3783	-5.8555	71.6976
GaMG	GDSC2; CTRP2	-5.6779	9.4908	-7.5827	65.9161
PFSK-1	GDSC2	-5.6693	1.3519	-6.2694	64.5215
GI-1	GDSC2	-5.3915	-3.2345	-5.3931	69.5592
D283 Med	GDSC2; CTRP2	-5.258	-1.0347	-5.2644	77.5064
AM-38	GDSC2; CTRP2	-4.8086	-0.2203	-4.823	74.6057
KALS-1	GDSC2; CTRP2	-4.5405	54.3619	-26.8605	53.5706
SF268	GDSC2; CTRP2	-4.4738	8.3977	-5.9246	63.8813
KS-1 [Human Krukenberg tumour]	GDSC2	-4.3601	6.0921	-6.5154	54.6296
Daoy	GDSC2; CTRP2	-4.3467	-2.0399	-4.3467	73.6687
YH-13	GDSC2; CTRP2	-4.1755	-1.2555	-4.1761	72.3468
A-172	GDSC2; CTRP2	-3.8408	2.151	-3.9405	67.7865
SK-MG-1	GDSC2	-2.3794	5.632	-4.2586	43.9602
YKG-1	CTRP2	-1.8765	16.5651	-6.2942	53.97
DK-MG	GDSC2; CTRP2	-1.4647	6.4863	-2.0991	54.0104
ONS-76	GDSC2; CTRP2	-1.4269	10.7732	-3.4388	52.9124
D-392MG	GDSC2	-1.3154	10.3434	-5.3963	40.9461
42-MG-BA	GDSC2; CTRP2	-0.7879	22.7604	-8.0274	50.244
D-263MG	GDSC2	-0.2871	10.5808	-4.5547	35.8508
LN-18	GDSC2; CTRP2	-0.195	4.0289	-0.283	46.9719
M059J	GDSC2	-0.1561	10.5759	-4.4328	35.1367
KNS-60	CTRP2	-0.1521	3704.3182	-1847.6077	49.9955
M059K	CTRP2	0.6355	110.5532	-50.1572	49.4566
SNU-466	CTRP2	0.994	9.1146	-0.2269	42.6183
TM-31	CTRP2	1.1168	7.1888	0.5313	40.8699
U-251MG	GDSC2; CTRP2	1.1693	35.5636	-12.378	47.1096
SW1088	GDSC2; CTRP2	2.1003	27.9659	-7.7892	44.3236
CAS-1	GDSC2; CTRP2	2.2563	15.8953	-1.8189	39.6277
LN-229	GDSC2; CTRP2	2.6434	10.3855	1.0379	33.2506
LN-405	GDSC2	2.6979	12.8725	-3.1602	22.8954
U-118MG	GDSC2; CTRP2	2.7543	22.2781	-4.4005	40.9965
SF126	CTRP2	3.1079	18.8269	-2.3921	38.7532
GB-1	GDSC2; CTRP2	3.7951	12.8228	1.1325	29.6296
KINGS-1	GDSC2	3.9414	16.1403	-3.8344	22.2917
GOS-3	CTRP2	4.5912	38.2799	-10.676	42.001
SNU-489	CTRP2	4.891	24.1498	-3.3765	35.9799
SNU-1105	CTRP2	5.8393	20.3777	-0.6651	29.601
KNS-42	CTRP2	5.85	51.574	-16.2378	42.5623
SF295	CTRP2	6.6362	19.5036	0.4571	25.3325
KG-1-C	CTRP2	7.2912	19.761	0.8757	24.0302
KNS-81	CTRP2	7.666	21.2661	0.4295	23.3925
SNU-626	CTRP2	7.7104	17.6616	2.2647	17.8379
SW1783	CTRP2	7.9104	11.2071	5.6159	4.4188
SNU-201	CTRP2	7.9409	9.2654	6.5422	0.7947
T98G	GDSC2; CTRP2	8.2884	22.8577	0.1334	22.5749
8-MG-BA	GDSC2; CTRP2	8.2894	26.4653	-1.6644	26.5504
SNU-738	CTRP2	8.301	25.754	-1.3004	26.245
DBTRG-05MG	GDSC2; CTRP2	8.4114	22.6672	0.3253	21.8768
U-87MG ATCC	GDSC2; CTRP2	8.7796	26.2642	-1.1762	24.7627
SNB-75	CTRP2	8.7916	25.3575	-0.7157	25.1385
GMS-10	CTRP2	10.6619	27.8086	-0.5157	20.8027
CCF-STTG1	CTRP2	12.2476	27.7103	0.6422	15.7191

Cancer Drug Sensitivity Data Curated from 2 Cell Line(s) in Digestive System Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
ETK-1	GDSC2	-1.4876	8.7591	-4.8008	40.7342
TGBC24TKB	GDSC2	-0.8787	8.0627	-3.8818	36.5099

Cancer Drug Sensitivity Data Curated from 23 Cell Line(s) in Endometrium Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
HEC-151	CTRP2	-8.1232	3.9434	-8.7791	77.4407
JHUEM-1	CTRP2	-6.9957	8.4996	-8.7036	70.1359
ESS-1	GDSC2; CTRP2	-4.7002	3.7321	-5.046	69.1713
AN3-CA	GDSC2; CTRP2	-4.0037	14.9442	-7.8211	58.9541
RL95-2	GDSC2; CTRP2	-3.3704	-2.1067	-3.3704	67.4743
JHUEM-7	CTRP2	-2.1915	7.9669	-3.306	57.7215
MFE-319	GDSC2; CTRP2	-1.8351	25.6797	-10.4266	52.2368
JHUEM-2	CTRP2	-1.7365	9.0129	-3.1456	55.5011
HEC-265	CTRP2	-1.6404	1.5433	-1.6477	57.8342
JHUEM-3	CTRP2	-1.0125	26.7481	-10.1364	51.074
HEC-50B	CTRP2	-0.4819	14.8727	-4.1214	50.0917
MFE-296	GDSC2; CTRP2	-0.3211	9.4591	-1.7683	48.3774
HEC-251	CTRP2	0.0082	5.6128	-0.2987	47.2239
HEC-1-A	CTRP2	1.1627	35.7753	-12.4883	48.2433
MFE-280	GDSC2	2.7622	12.1437	-2.7483	21.1568
HEC-108	CTRP2	3.0934	11.2692	1.1283	32.4511
HEC-59	CTRP2	4.1949	13.2884	1.3056	28.7841
KLE	GDSC2; CTRP2	4.7882	23.2691	-3.0305	35.2217
EFE-184	CTRP2	5.8143	16.8535	1.067	25.4609
HEC-6	CTRP2	6.1973	15.7679	1.9443	21.9659
EN	GDSC2; CTRP2	9.7155	27.5674	-1.1012	23.1405
HEC-1-B	CTRP2	11.6422	22.999	2.4778	11.08
Ishikawa (Heraklio) 02 ER-	CTRP2	-2.2739	-1.8568	-2.2739	62.172

Cancer Drug Sensitivity Data Curated from 30 Cell Line(s) in Kidney Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
SW13	GDSC2	-6.053	-1.8089	-6.1257	71.9337
BFTC-909	GDSC2; CTRP2	-2.4989	5.8022	-3.0625	59.0219
RXF 393L	GDSC2	-0.8993	10.4896	-5.0759	38.9706
KMRC-3	CTRP2	-0.6327	11.1832	-2.7473	52.7375
TUHR4TKB	CTRP2	-0.555	9.2089	-1.9328	50.4642
KTCTL-195	GDSC2	-0.2523	11.4266	-4.9399	36.5201
KMRC-1	CTRP2	-0.2211	12.0863	-2.6716	49.0922
LB996-RCC	GDSC2	0.0083	15.25	-6.6022	38.4316
NCC010	GDSC2	0.3601	8.1974	-2.7903	28.5197
786-O	GDSC2; CTRP2	0.6411	5.5683	0.3946	41.9944
CAL-54	GDSC2; CTRP2	1.0157	10.6122	-0.7713	42.2678
SN12C	GDSC2	1.0444	11.6697	-3.9146	29.9626
HA7-RCC	GDSC2	1.8575	11.4847	-3.1397	25.0737
UO-31	CTRP2	2.1811	12.4599	-0.3301	40.3855
A-704	GDSC2	2.42	7.6628	-0.7892	12.5141
TK-10	GDSC2	2.6142	12.0252	-2.8042	21.7588
769-P	GDSC2; CTRP2	3.4214	13.0822	0.6417	31.9201
ACHN	GDSC2; CTRP2	4.3271	14.5768	0.8168	29.0645
Caki-2	CTRP2	5.6501	31.924	-6.5898	37.8771
VMRC-RCZ	GDSC2; CTRP2	5.9232	16.9438	1.1183	24.5069
VMRC-RCW	CTRP2	6.6678	16.4147	2.0275	20.6889
TUHR10TKB	CTRP2	7.0442	37.4037	-8.1501	37.0495
Caki-1	CTRP2	7.4405	18.6664	1.5451	20.6679
KMRC-2	CTRP2	8.4743	15.1426	4.0995	9.6976
TUHR14TKB	CTRP2	8.771	11.0741	6.2014	1.2961
A-498	GDSC2; CTRP2	8.9682	20.2248	1.9643	16.228
SNU-1272	CTRP2	10.0005	25.5097	0.128	20.2225
RCC10RGB	GDSC2; CTRP2	10.6157	25.1352	0.7579	17.2843
KMRC-20	GDSC2; CTRP2	10.8465	25.4853	0.7512	16.9766
OS-RC-2	GDSC2; CTRP2	12.445	26.5721	1.313	13.3326

Cancer Drug Sensitivity Data Curated from 58 Cell Line(s) in Large Intestine Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
RKO	GDSC2; CTRP2	-10.6391	18.3074	-16.1844	67.6145
SNU-175	GDSC2; CTRP2	-6.2663	3.8039	-6.745	73.3233
KM12	GDSC2; CTRP2	-6.0985	15.6378	-10.3113	62.7692
GP5d	GDSC2	-6.0034	-4.2456	-6.0035	75.7489
SW48	GDSC2; CTRP2	-5.4649	5.5401	-6.2311	69.2212
HCC2998	GDSC2	-4.5552	15.3786	-10.9181	53.1084
SNU-C5	GDSC2; CTRP2	-3.9831	32.2208	-15.6133	54.9085
DiFi	GDSC2	-3.8654	0.772	-4.1626	53.8805
SK-CO-1	GDSC2; CTRP2	-3.7578	10.6154	-5.8878	60.4342
SNU-81	GDSC2; CTRP2	-3.0914	5.6067	-3.6633	61.5877
GP2d	CTRP2	-2.6839	0.7116	-2.6897	64.5924
SW948	GDSC2; CTRP2	-2.5347	4.6385	-2.8667	59.8832
LS513	GDSC2; CTRP2	-2.4244	1.5059	-2.4425	60.9831
T84	GDSC2; CTRP2	-2.3592	4.0815	-2.5888	59.3737
COLO 320HSR	GDSC2	-2.1341	3.0257	-2.9417	40.1265
HT115	GDSC2; CTRP2	-2.0554	1.6945	-2.0721	58.7225
COLO205	GDSC2; CTRP2	-1.6426	18.5763	-6.9485	52.4735
SNU-61	GDSC2; CTRP2	-1.3348	10.9682	-3.4138	52.5384
SNU-C2B	GDSC2	-1.2364	10.9633	-5.6223	40.9674
SNU-407	GDSC2; CTRP2	-1.0547	6.4303	-1.6381	51.9789
LoVo	GDSC2; CTRP2	-0.8337	7.2398	-1.6116	50.7854
HCT 15	GDSC2; CTRP2	-0.6929	2.2102	-0.7006	50.0906
CCK-81	GDSC2; CTRP2	-0.599	2.6732	-0.6168	49.4876
LS180	GDSC2; CTRP2	-0.4386	5.2367	-0.7112	48.5908
SNU-1040	GDSC2	-0.4143	12.5574	-5.6451	38.2767
SNU-C1	GDSC2; CTRP2	-0.3679	9.2094	-1.7307	48.571
SNU-C4	CTRP2	-0.3076	3.8042	-0.3806	52.3523
NCI-H508	CTRP2	-0.14	3.9966	-0.222	47.9787
SNU-C2A	CTRP2	-0.0308	8.9527	-1.2768	47.9545
CaR-1	GDSC2	0.0404	8.319	-3.1424	30.9029
HCC-56	CTRP2	0.4843	5.9548	0.1478	44.331
NCI-H716	GDSC2; CTRP2	0.6642	4.8569	0.5325	41.6072
SW626	GDSC2	0.7594	11.059	-3.8565	30.6715
CW-2	GDSC2; CTRP2	0.7935	11.578	-1.396	43.7625
NCI-H747	GDSC2; CTRP2	1.4409	15.4267	-2.4132	42.609
SW837	GDSC2	1.7201	12.4052	-3.713	27.3912
COLO 320	CTRP2	2.0262	7.3379	1.4806	35.08
SW1463	GDSC2	2.1842	11.0921	-2.6789	22.4054
LS1034	GDSC2; CTRP2	2.3138	7.2653	1.8154	32.1507
C2BBe1	GDSC2; CTRP2	2.6604	16.3394	-1.6315	38.2702
CL-11	GDSC2; CTRP2	2.8517	11.5334	0.7643	33.2858
SNU-1033	CTRP2	3.569	14.9637	-0.0968	35.5216
HT-55	GDSC2; CTRP2	3.7488	10.4572	2.1567	26.7185
OUMS-23	CTRP2	4.0282	18.7223	-1.4782	35.2074
MDST8	GDSC2; CTRP2	4.4539	90.3128	-36.7822	46.7314
HCT 8	CTRP2	4.9927	9.8756	3.6835	19.8208
LS411N	GDSC2; CTRP2	5.1609	23.5643	-2.8468	34.2216
SW1116	GDSC2; CTRP2	5.378	15.2955	1.4465	24.7756
SNU-503	CTRP2	5.6294	30.6001	-5.9466	37.3514
DLD-1	CTRP2	6.1905	22.1167	-1.2288	30.0027
HCT 116	GDSC2; CTRP2	6.5781	17.3777	1.4699	22.1079
SW1417	GDSC2; CTRP2	7.6529	21.8619	0.1213	23.7263
COLO201	CTRP2	7.8544	19.5412	1.4421	20.1994
COLO 678	GDSC2; CTRP2	8.533	20.506	1.4945	18.4041
RCM-1 [Human ESC]	GDSC2; CTRP2	8.9283	15.4322	4.2804	8.0575
LS123	GDSC2; CTRP2	9.7641	41.1473	-7.8125	32.8579
HT-29	GDSC2; CTRP2	13.4752	27.3425	1.6039	11.3266
SW620	GDSC2; CTRP2	13.9619	35.7978	-2.0735	19.5741

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Leukemia Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
MO-T	GDSC2	2.294	9.4783	-1.7875	18.1479

Cancer Drug Sensitivity Data Curated from 26 Cell Line(s) in Liver Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
SNU-182	CTRP2	-8.2124	22.9745	-15.6075	63.0555
SNU-398	GDSC2; CTRP2	-6.8429	13.6102	-10.3078	65.2019
PLC/PRF/5	CTRP2	-6.7753	52.8713	-28.2169	55.7596
HuH-6	CTRP2	-5.091	22.1947	-12.0691	58.9679
HLE	GDSC2	-4.4233	1.9754	-5.0827	57.1047
HLF	CTRP2	-4.2573	11.46	-6.7316	61.9844
JHH-5	CTRP2	-2.7946	13.2094	-5.8426	57.3466
SNU-423	GDSC2; CTRP2	-2.7767	5.1403	-3.2228	60.6313
SNU-878	CTRP2	-2.4486	3.337	-2.5891	61.7468
JHH-4	GDSC2; CTRP2	-0.5596	7.2296	-1.3096	49.3843
JHH-2	GDSC2; CTRP2	-0.3311	15.6012	-4.2865	48.9026
JHH-7	GDSC2	0.0536	10.1366	-4.0257	33.4403
Li-7	CTRP2	0.441	10.2715	-1.2502	45.9168
JHH-1	GDSC2; CTRP2	0.7809	8.1555	-0.1292	42.2992
HuH-1	GDSC2; CTRP2	1.7736	9.8162	0.3467	37.7194
SNU-886	CTRP2	2.3911	16.5851	-2.0103	40.1894
Hep-G2/C3A	GDSC2	2.5728	9.4001	-1.5329	16.1436
SK-HEP-1	GDSC2; CTRP2	2.8467	22.1649	-4.259	40.6743
Huh-7	GDSC2	3.8274	7.712	0.1268	4.3798
SNU-449	GDSC2; CTRP2	4.0691	9.8385	2.755	23.8201
SNU-761	CTRP2	4.1162	21.0006	-2.5153	36.5195
Hep-G2	CTRP2	7.2896	14.4662	3.5207	14.0286
JHH-6	GDSC2; CTRP2	7.6423	9.3361	6.3324	1.8508
SNU-475	CTRP2	9.1074	22.5665	0.9122	19.5517
Hep 3B2.1-7	GDSC2; CTRP2	10.3129	22.5004	1.8245	14.6241
SNU-387	GDSC2; CTRP2	10.7887	40.6568	-6.7684	30.5153

Cancer Drug Sensitivity Data Curated from 194 Cell Line(s) in Lung Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
NCI-H446	GDSC2; CTRP2	-16.2385	9.2551	-19.0061	78.5748
NCI-H522	GDSC2; CTRP2	-12.2344	7.2987	-14.0693	77.4228
NCI-H2110	CTRP2	-11.92	6.1312	-13.4136	78.8747
HCC1438	CTRP2	-11.4944	9.3359	-13.8617	76.3024
COR-L279	CTRP2	-11.25	3.3251	-12.0447	81.7133
NCI-H841	GDSC2; CTRP2	-11.245	9.0939	-13.5153	74.7472
LCLC-97TM1	GDSC2; CTRP2	-10.3008	18.126	-15.7538	67.335
DV-90	CTRP2	-10.2758	1.4041	-10.6713	83.6903
NCI-H1105	CTRP2	-8.9886	13.5515	-12.5855	68.9701
COR-L51	CTRP2	-8.8612	1.6791	-9.199	81.8743
NCI-H524	GDSC2; CTRP2	-8.5916	0.7543	-8.8028	82.2306
SCLC-21H	CTRP2	-8.2759	11.8654	-11.2078	69.2363
NCI-H322	CTRP2	-8.0651	13.2889	-11.4967	67.8803
DMS 273	GDSC2; CTRP2	-7.7674	3.565	-8.3227	76.5928
NCI-H82	GDSC2	-7.5248	-3.4107	-7.5535	82.343
NCI-H889	CTRP2	-7.3576	8.5789	-9.122	70.6833
NCI-H2081	CTRP2	-6.9766	3.4243	-7.4446	76.311
NCI-H810	GDSC2; CTRP2	-6.8448	10.1445	-9.0659	67.699
NCI-H520	GDSC2; CTRP2	-6.4924	7.6824	-7.9121	69.2552
NCI-H1048	GDSC2	-6.4252	6.5885	-8.8943	61.8587
NCI-H1975	GDSC2; CTRP2	-6.3834	11.5669	-9.0595	65.7539
LK2	CTRP2	-6.3789	-2.9879	-6.3795	86.4082
EMC-BAC-2	GDSC2	-6.3185	1.2442	-6.9497	67.5005
NCI-H1694	GDSC2; CTRP2	-6.2996	1.4101	-6.4537	76.9746
LK-2	GDSC2	-6.1465	-1.958	-6.2114	72.7512
Lu-99	CTRP2	-5.9619	6.6922	-7.0589	70.0042
NCI-H1876	GDSC2	-5.958	8.0718	-9.0138	59.4365
NCI-H146	CTRP2	-5.8225	12.8392	-8.9242	64.4573
NCI-H526	GDSC2; CTRP2	-5.7704	-4.3651	-5.7704	82.9873
NCI-H23	GDSC2; CTRP2	-5.6795	-2.7938	-5.6797	81.4408
HARA [Human squamous cell lung carcinoma]	GDSC2; CTRP2	-5.5718	-0.0352	-5.6056	77.2356
SBC-5	GDSC2; CTRP2	-5.4076	-3.867	-5.4076	80.6362
NCI-H1581	GDSC2; CTRP2	-5.2782	-0.5256	-5.2928	76.9065
NCI-H211	GDSC2; CTRP2	-5.237	-2.5046	-5.2372	78.974
RERF-LC-A1	CTRP2	-5.2298	-2.9928	-5.2298	81.4765
HCC44	GDSC2; CTRP2	-5.1161	7.856	-6.4614	66.005
DMS 114	GDSC2; CTRP2	-5.0854	5.9894	-5.9241	67.7402
Lu-65	GDSC2; CTRP2	-5.0187	3.8017	-5.3999	70.0691
NCI-H3122	GDSC2	-4.8908	9.5711	-8.5656	55.3956
COR-L88	CTRP2	-4.8426	7.5798	-6.0826	66.448
NCI-H1703	CTRP2	-4.5231	-3.453	-4.5231	77.211
SBC-3	GDSC2	-4.5171	5.5978	-6.4788	55.5279
NCI-H1341	CTRP2	-4.3646	-3.7933	-4.3646	76.1543
COR-L47	CTRP2	-4.2813	29.6387	-14.6833	56.0506
CPC-N	GDSC2	-3.9961	3.5972	-5.1535	53.7032
NCI-H250	GDSC2	-3.9903	8.5818	-7.2082	52.4361
Lu-139	GDSC2	-3.7212	12.2082	-8.6072	51.0739
NCI-H1155	GDSC2; CTRP2	-3.711	-0.6667	-3.7122	69.386
NCI-H661	GDSC2; CTRP2	-3.6998	7.8588	-4.9178	62.0416
NCI-H209	GDSC2; CTRP2	-3.5395	48.0178	-22.8281	53.0171
NCI-H2087	GDSC2; CTRP2	-3.4981	24.6116	-11.566	55.329
NCI-H2029	GDSC2; CTRP2	-3.4037	5.6084	-4.0034	62.7792
DMS 454	CTRP2	-3.3599	13.2252	-6.4477	60.3696
VMRC-LCD	GDSC2; CTRP2	-3.2933	10.3983	-5.3094	59.2362
COR-L311	GDSC2	-3.1802	1.7225	-3.6536	48.2415
NCI-H1339	CTRP2	-3.1309	-0.0298	-3.133	67.6005
NCI-H2171	CTRP2	-3.0691	1.0703	-3.0868	66.6295
Ms-1	GDSC2	-3.0216	3.7603	-4.1677	47.4816
NCI-H1184	CTRP2	-3.0141	6.0717	-3.6865	62.1094
LC-1/sq	GDSC2	-2.9691	2.6467	-3.7108	46.7756
NCI-H838	CTRP2	-2.9294	-0.9572	-2.9295	66.5333
IST-SL2	GDSC2	-2.5052	6.6179	-4.8213	45.2042
NCI-H2795	GDSC2	-2.4859	8.0534	-5.4521	45.6442
HCC4006	CTRP2	-2.2515	15.6038	-6.2659	55.1533
SK-MES-1	GDSC2; CTRP2	-2.0545	11.6392	-4.4392	54.8952
NCI-H69	CTRP2	-2.0165	8.9015	-3.4124	56.6193
NCI-H1963	GDSC2	-1.7504	14.5658	-7.8586	44.6733
NCI-H1666	GDSC2; CTRP2	-1.6962	13.2694	-4.7077	53.3767
NCI-H2141	GDSC2; CTRP2	-1.5708	9.43	-3.1082	53.7375
SHP-77	GDSC2; CTRP2	-1.5454	0.8849	-1.5464	55.6146
HCC2279	CTRP2	-1.4041	9.3281	-2.8926	54.0861
UMC-11	GDSC2	-1.3881	5.491	-3.1824	36.912
Lu-99A	GDSC2	-1.2718	18.5957	-9.4045	44.2913
NCI-H1944	GDSC2; CTRP2	-1.231	17.3724	-5.9911	51.5262
NCI-H2461	GDSC2	-1.182	8.1615	-4.2209	38.474
NCI-H2804	GDSC2	-1.1559	6.6552	-3.4843	36.674
RERF-LC-Sq1	GDSC2	-1.1186	7.2323	-3.7186	37.1012
HCC827	GDSC2; CTRP2	-1.0484	10.1169	-2.7892	51.5347
NCI-H2170	GDSC2; CTRP2	-0.7423	6.7955	-1.3906	50.3333
COR-L95	CTRP2	-0.7014	6.7326	-1.3295	51.3279
NCI-H1573	CTRP2	-0.6583	23.7634	-8.3743	50.4432
NCI-H1734	CTRP2	-0.6155	5.7003	-0.9928	50.9312
DMS 53	GDSC2; CTRP2	-0.594	5.6679	-0.9628	49.5182
NCI-H1355	GDSC2; CTRP2	-0.5823	17.4728	-5.3789	49.7261
PC-14	GDSC2; CTRP2	-0.5227	80.6924	-36.275	49.8948
NCI-H2373	GDSC2	-0.4876	7.8296	-3.397	33.6843
NCI-H1651	GDSC2; CTRP2	-0.4424	17.4361	-5.2212	49.3234
HCC366	GDSC2; CTRP2	-0.4224	14.514	-3.9043	49.1465
NCI-H2818	GDSC2	-0.3499	9.2199	-3.9445	34.6529
COR-L23	GDSC2	-0.3414	11.7199	-5.1656	37.2342
NCI-H1993	GDSC2	-0.1735	12.7524	-5.5244	37.3292
COLO 699	CTRP2	-0.0842	6.6842	-0.6436	47.9295
COLO 668	GDSC2; CTRP2	-0.0489	10.6618	-1.9231	47.3094
HCC1588	CTRP2	-0.027	4.4643	-0.153	47.2894
HCC95	CTRP2	0.0796	7.4056	-0.6625	47.1195
NCI-H596	GDSC2	0.0803	20.8741	-9.3405	41.1125
LUDLU-1	CTRP2	0.1791	10.4242	-1.5884	47.1871
NCI-H2286	CTRP2	0.3767	10.86	-1.5473	46.3682
NCI-H2106	CTRP2	0.3959	27.6321	-9.2178	48.3368
NCI-H322M	GDSC2	0.4026	20.5253	-8.8877	40.008
NCI-H1092	GDSC2; CTRP2	0.5998	13.7247	-2.508	45.2967
NCI-H2731	GDSC2	0.8123	10.1338	-3.3493	28.9455
Calu-6	GDSC2; CTRP2	1.0019	35.2634	-12.3833	47.3612
NCI-H292	CTRP2	1.0529	35.4044	-12.4061	47.6372
NCI-H358	GDSC2; CTRP2	1.1028	60.369	-24.7316	48.3604
NCI-H1568	GDSC2; CTRP2	1.1452	16.2424	-3.0827	44.0066
NCI-H1838	CTRP2	1.1887	9.9614	-0.333	41.9943
NCI-H720	GDSC2	1.2091	19.0263	-7.4509	36.5567
Sq-1	CTRP2	1.2297	17.9738	-3.8015	44.8973
Calu-3	GDSC2; CTRP2	1.2467	10.7805	-0.5939	41.1941
LXF 289	GDSC2; CTRP2	1.2925	11.678	-0.9145	41.4654
NCI-H2369	GDSC2	1.3711	14.4977	-5.0505	31.9328
NCI-H2227	GDSC2	1.4725	14.2883	-4.8607	31.2193
NCI-H650	GDSC2; CTRP2	1.4851	13.299	-1.4124	41.4384
LCLC-103H	GDSC2; CTRP2	1.544	220.1574	-104.1442	49.4418
A-549	GDSC2; CTRP2	1.5847	13.8161	-1.5401	41.273
RERF-LC-KJ	GDSC2	1.6009	10.2143	-2.7164	24.219
NCI-H2869	GDSC2	1.802	16.3036	-5.5942	31.9954
MOR/CPR	CTRP2	1.8497	8.739	0.8303	37.3719
LOU-NH91	GDSC2; CTRP2	1.8671	83.4597	-35.573	48.2927
A-427	GDSC2	1.878	20.8168	-7.7879	35.5254
ABC-1	GDSC2	1.8858	8.0121	-1.3815	17.2297
NCI-H2803	GDSC2	1.9713	6.0829	-0.3507	11.1036
LC-1/sq-SF	CTRP2	2.4256	13.2582	-0.4372	37.8787
NCI-H345	GDSC2	2.5283	10.445	-2.0855	18.9276
NCI-H2810	GDSC2	2.5571	11.4489	-2.5621	20.9286
EPLC-272H	GDSC2	2.5792	24.0233	-8.8168	35.4389
NCI-H1395	CTRP2	2.6235	11.911	0.3646	35.7326
NCI-H1693	GDSC2; CTRP2	2.6445	12.2119	0.2533	35.0753
NCI-H2595	GDSC2	2.6927	14.7545	-4.101	26.0252
NCI-H1781	GDSC2	2.7001	21.3376	-7.3781	33.1888
KNS-62	GDSC2; CTRP2	2.7019	16.984	-1.8968	38.5172
HCC1833	CTRP2	2.7604	14.8769	-0.8465	37.5443
Lu-135	GDSC2	2.8609	20.816	-6.989	32.2136
NCI-H2023	GDSC2; CTRP2	2.9842	12.0266	0.6819	33.0858
NCI-H1915	GDSC2; CTRP2	3.1587	21.031	-3.4149	39.1757
CAL-12T	CTRP2	3.1697	13.7956	0.0614	34.6976
NCI-H2009	CTRP2	3.2192	15.6251	-0.7499	36.0854
NCI-H513	GDSC2	3.3884	6.0136	0.6315	2.3939
NCI-H1623	GDSC2; CTRP2	3.4199	14.4568	-0.0018	33.3798
NCI-H2135	GDSC2	3.4585	10.6554	-1.4996	13.8353
NCI-H2122	GDSC2; CTRP2	3.4983	12.4983	0.9873	30.8368
EBC-1	GDSC2; CTRP2	3.5293	39.1116	-12.0188	43.6571
Lu-165	GDSC2	3.5298	15.9627	-4.0544	23.9051
NCI-H2591	GDSC2	3.6948	7.453	0.1668	4.373
HCC78	GDSC2; CTRP2	3.698	15.8092	-0.3764	33.4082
HCC2108	CTRP2	3.8665	14.0469	0.627	31.456
DMS 79	GDSC2; CTRP2	3.8729	16.4324	-0.5099	33.2244
NCI-H1299	GDSC2; CTRP2	3.9295	15.0259	0.221	31.5344
NCI-H3255	GDSC2	4.0549	16.4274	-3.892	22.2321
NCI-H2228	GDSC2; CTRP2	4.1193	32.6753	-8.2971	41.1236
NCI-H647	CTRP2	4.1472	26.8634	-5.3855	39.4873
NCI-H1869	GDSC2; CTRP2	4.171	17.1176	-0.5617	32.5863
NCI-H2722	GDSC2	4.278	19.7846	-5.3796	25.96
NCI-H2085	GDSC2; CTRP2	4.2981	20.1937	-1.9517	34.7195
ChaGo-K-1	CTRP2	4.738	85.6143	-34.193	46.4915
NCI-H1792	GDSC2; CTRP2	4.8388	16.8072	0.2093	29.3138
NCI-H2405	GDSC2; CTRP2	4.8481	12.9088	2.1164	23.9599
NCI-H2126	CTRP2	4.9123	21.9341	-2.2575	34.3658
NCI-H2342	CTRP2	4.9236	16.5344	0.4212	29.2315
NCI-H1435	GDSC2; CTRP2	5.2218	12.3688	2.7322	20.9618
HOP-92	GDSC2; CTRP2	5.39	20.1467	-0.9453	30.5656
NCI-H2030	CTRP2	5.4099	14.8281	1.7059	24.5181
HCC2935	CTRP2	5.6139	22.064	-1.7022	33.2472
NCI-H460	CTRP2	5.6332	16.1975	1.2313	25.4079
NCI-H727	GDSC2; CTRP2	5.9658	13.9293	2.6532	19.5441
COR-L105	GDSC2; CTRP2	6.2009	21.6937	-1.0086	29.025
HOP-62	GDSC2; CTRP2	6.3239	17.9478	0.9672	24.0812
EKVX	GDSC2; CTRP2	6.742	16.1912	2.2022	19.4611
NCI-H1373	CTRP2	6.8085	16.3029	2.2027	19.8166
NCI-H2196	CTRP2	6.8904	16.615	2.1156	19.9393
BEN	CTRP2	7.2245	8.3325	6.5272	1.7287
T3M-10	CTRP2	7.2461	37.1501	-7.8555	36.5334
NCI-H1563	GDSC2; CTRP2	7.3844	9.0427	6.2957	2.3609
RERF-LC-Ad1	CTRP2	7.4494	8.743	6.4867	1.5546
HCC1171	CTRP2	7.503	16.5359	2.66	16.8606
NCI-H1650	GDSC2; CTRP2	7.6289	29.392	-3.6611	30.9838
NCI-H2291	CTRP2	7.8021	17.2737	2.5311	16.7534
NCI-H196	GDSC2; CTRP2	7.8058	20.6706	0.8396	21.5681
RERF-LC-Ad2	CTRP2	7.8979	26.3366	-1.9151	28.1253
NCI-H1755	GDSC2; CTRP2	7.9862	18.7438	1.9442	17.9544
NCI-H2444	CTRP2	8.041	9.7147	6.4004	1.1877
NCI-H1793	GDSC2; CTRP2	9.2337	35.3915	-5.3641	30.8707
SW1271	GDSC2; CTRP2	9.9531	39.3886	-6.7879	31.5732
NCI-H2172	CTRP2	10.0326	21.9897	1.8749	15.2184
HCC15	GDSC2; CTRP2	10.3773	30.5465	-2.0742	24.1463
IA-LM	GDSC2; CTRP2	10.5359	19.1978	3.5545	8.5863
SW1573	GDSC2; CTRP2	11.1773	36.5	-4.4132	26.9963
NCI-H226	GDSC2; CTRP2	11.3174	23.7817	1.8953	13.0383
SK-LU-1	GDSC2; CTRP2	11.7507	30.2965	-0.9483	19.9298
NCI-H441	GDSC2; CTRP2	12.5481	29.0675	0.1953	16.1929
HCC1195	CTRP2	13.0138	50.8485	-10.1198	31.6343
Calu-1	CTRP2	13.5089	34.3959	-1.7086	20.352
Hs 888.Lu	CTRP2	5.1725	20.4286	-1.2786	32.2325

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Lymphoma Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
CBTCi002-A	GDSC2	-3.926	2.6502	-4.7507	53.6106

Cancer Drug Sensitivity Data Curated from 3 Cell Line(s) in Thigh Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
SYO-1	CTRP2	-9.0114	12.2875	-12.1514	69.9253
H-STS	CTRP2	-4.4305	-2.9107	-4.4305	76.5655
P-STS	CTRP2	-0.4123	6.5322	-0.9629	49.7695

Cancer Drug Sensitivity Data Curated from 42 Cell Line(s) in Ovary Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
2004	CTRP2	-0.7951	14.4952	-4.2815	51.12
A2780	GDSC2; CTRP2	-12.6447	5.0281	-13.931	80.176
ONCO-DG-1	CTRP2	-9.1504	18.0613	-14.5128	66.427
TOV-112D	GDSC2; CTRP2	-6.9559	-1.7532	-6.9687	84.0778
OC 314	CTRP2	-6.8649	0.3243	-6.9575	83.8006
COV434	CTRP2	-6.4215	10.6948	-8.7942	68.5698
SNU-8	CTRP2	-6.2133	29.6737	-16.6051	58.5806
OVCAR-3	GDSC2	-5.8846	5.5035	-7.893	60.9818
OVK18	GDSC2; CTRP2	-4.4889	13.3952	-7.714	60.7432
MCAS	CTRP2	-3.8651	-1.3677	-3.8652	72.6043
ES-2	GDSC2	-2.9061	2.9971	-3.7634	46.408
COV644	CTRP2	-2.5462	17.5745	-7.4238	55.3946
IGROV-1	GDSC2; CTRP2	-1.3412	6.6013	-1.9936	53.3835
TOV-21G	GDSC2; CTRP2	-0.8868	12.3237	-3.4698	50.763
OAW42	GDSC2; CTRP2	0.1478	5.7273	-0.1703	45.1338
Caov-3	CTRP2	0.1817	478.2825	-234.3322	49.927
SNU-119	CTRP2	0.2973	87.2765	-38.8381	49.527
JHOM-1	CTRP2	0.408	21.034	-6.0451	47.82
OV-90	GDSC2; CTRP2	0.6903	9.3339	-0.6332	43.3398
ES2	CTRP2	1.4865	9.1646	0.2853	39.8555
TYK-nu	GDSC2; CTRP2	1.5681	43.1922	-15.7874	47.0783
EFO-21	GDSC2; CTRP2	1.762	14.0955	-1.4857	40.6599
RMG-I	CTRP2	2.1924	15.9598	-1.9121	40.6379
COV362	CTRP2	2.3097	29.5515	-8.3759	44.6107
OVCAR-8	GDSC2; CTRP2	3.0387	18.8183	-2.4536	38.3687
OV56	GDSC2; CTRP2	3.4316	12.767	0.7972	31.5093
OV7	CTRP2	3.4505	41.042	-13.0487	44.4069
OAW28	GDSC2; CTRP2	4.3061	18.0955	-0.9139	32.9384
OVCAR-4	GDSC2; CTRP2	4.6675	19.2283	-1.1393	32.5198
JHOC-5	CTRP2	5.3162	12.515	2.7507	21.2463
SK-OV-3	GDSC2; CTRP2	5.3868	22.5255	-2.1311	32.6872
OVCAR-5	GDSC2; CTRP2	6.1744	24.1829	-2.2744	31.383
DOV13	GDSC2; CTRP2	6.6682	27.0814	-3.3038	32.0759
FU-OV-1	CTRP2	7.1153	8.5629	6.3281	2.7544
JHOS-2	CTRP2	8.1145	17.9047	2.4624	16.4239
OVISE	GDSC2; CTRP2	8.173	22.1598	0.3899	22.1203
OVTOKO	GDSC2; CTRP2	8.6418	22.0116	0.8308	20.1372
SNU-840	CTRP2	8.6572	10.4396	6.4077	0.6789
HEY A8	CTRP2	11.216	30.5123	-1.4374	22.0567
OVSAHO	CTRP2	11.5362	18.68	4.3865	4.7888
Kuramochi	GDSC2; CTRP2	12.4108	33.8878	-2.2276	21.7307
EFO-27	GDSC2; CTRP2	13.2528	49.7541	-9.3994	30.4768

Cancer Drug Sensitivity Data Curated from 26 Cell Line(s) in Soft Tissue Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
Yamato-SS	CTRP2	5.3588	31.856	-6.8066	38.5232
KYM-1	GDSC2; CTRP2	-12.4437	15.0265	-16.8411	71.3852
TE 617.T	CTRP2	-11.0553	14.1325	-15.02	70.9977
HT-1080	GDSC2; CTRP2	-10.7861	10.8739	-13.5859	72.7041
Rh41	GDSC2; CTRP2	-9.2755	4.793	-10.2086	77.1301
EW-8	GDSC2	-7.6197	-6.6333	-7.6197	91.6097
GCT	GDSC2; CTRP2	-7.3106	7.9347	-8.878	70.5448
G-402	GDSC2; CTRP2	-5.0478	11.0045	-7.4181	63.3983
RD	GDSC2; CTRP2	-4.4986	8.9083	-6.1122	63.553
G-401	GDSC2; CTRP2	-3.9435	-1.0662	-3.9441	70.9153
TTC-709	CTRP2	-3.8012	10.5355	-5.9062	61.4014
SW982	GDSC2; CTRP2	-3.0085	2.5038	-3.0989	63.6115
Hs 729.T	CTRP2	-2.5949	37.0145	-16.5867	52.924
MES-SA	GDSC2; CTRP2	-2.5362	10.1609	-4.408	56.9855
SK-UT-1	GDSC2; CTRP2	-2.0391	9.3865	-3.6001	55.5397
Rh30	GDSC2	-1.9382	5.9228	-3.9343	41.2605
A-204	GDSC2; CTRP2	-1.5459	18.7045	-6.9085	52.2228
RKN	GDSC2; CTRP2	-1.4773	4.0193	-1.6393	54.7212
BT-16	CTRP2	-0.6874	3.5372	-0.7559	51.4988
VA-ES-BJ	GDSC2	-0.062	5.6012	-1.9193	26.4838
Tm87-16	CTRP2	0.0953	11.1424	-1.9576	47.6828
TE 441.T	CTRP2	0.1483	110.8291	-50.7152	49.7017
SK-LMS-1	GDSC2; CTRP2	0.1908	17.8958	-4.7954	47.492
SW872	GDSC2	1.5846	7.1764	-1.2111	17.2002
SW684	GDSC2	4.2417	15.1034	-3.1084	19.1067
Rh18	CTRP2	7.2423	24.8385	-1.7031	28.8903

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Clivus Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
U-CH1	CTRP2	6.3037	9.4965	5.145	9.433

Cancer Drug Sensitivity Data Curated from 8 Cell Line(s) in Pleura Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
NCI-H28	GDSC2; CTRP2	-5.5397	-3.9042	-5.5397	81.4535
MSTO-211H	GDSC2; CTRP2	-2.8643	9.0624	-4.3861	58.5867
MPP 89	GDSC2; CTRP2	-0.9513	5.0291	-1.2276	51.5715
JL-1	CTRP2	0.144	19.8427	-5.7443	48.4236
IST-Mes1	GDSC2; CTRP2	2.9651	14.074	-0.2706	35.1899
NCI-H2452	CTRP2	4.9758	27.8447	-5.1399	37.7357
ACC-MESO-1	CTRP2	10.017	20.9329	2.3771	13.6183
NCI-H2052	GDSC2; CTRP2	12.332	27.2781	0.9044	14.6032

Cancer Drug Sensitivity Data Curated from 7 Cell Line(s) in Prostate Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
LNCaP clone FGC	GDSC2; CTRP2	-6.0642	3.3714	-6.4538	73.4484
22Rv1	GDSC2; CTRP2	-3.7653	5.3409	-4.3378	64.32
VCaP	GDSC2; CTRP2	-2.3098	12.3843	-5.0011	55.4822
NCI-H660	CTRP2	-1.1734	14.9136	-4.8529	52.2621
PC-3	GDSC2	-0.9256	12.1174	-5.8963	40.2787
DU145	GDSC2; CTRP2	1.1708	37.6034	-13.382	47.263
PaCa-3	CTRP2	6.8006	30.2134	-4.7584	34.1842

Cancer Drug Sensitivity Data Curated from 2 Cell Line(s) in Salivary Gland Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
YD-15	CTRP2	-3.1182	-2.5081	-3.1182	67.8185
A-253	GDSC2; CTRP2	2.1866	23.2642	-5.4122	42.9539

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Small Intestine Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
HuTu 80	GDSC2	-5.9649	-1.4091	-6.0708	70.6519

Cancer Drug Sensitivity Data Curated from 40 Cell Line(s) in Stomach Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
SNU-16	CTRP2	-9.2717	-7.6276	-9.2717	99.2294
ECC10	GDSC2; CTRP2	-9.1517	7.6795	-10.8126	73.6525
RF-48	GDSC2	-8.2704	-4.6129	-8.2793	87.9068
IM95	GDSC2; CTRP2	-8.2489	3.259	-8.7875	77.7952
SH-10-TC	CTRP2	-6.6114	30.0037	-17.1532	58.9885
GSS	CTRP2	-5.0858	-3.0666	-5.0858	80.7051
Fu97	CTRP2	-5.0795	19.0661	-10.6815	60.0036
SK-GT-2	GDSC2	-4.529	8.7848	-7.8474	54.4111
23132/87	GDSC2; CTRP2	-4.1081	-2.793	-4.1081	72.2616
SNU-620	CTRP2	-3.6884	-1.4855	-3.6884	71.5351
ECC12	CTRP2	-3.508	-2.4727	-3.508	70.4249
HGC-27	GDSC2; CTRP2	-3.0447	13.4385	-6.1989	57.2113
SNU-5	GDSC2; CTRP2	-2.9131	-1.3458	-2.9131	64.5037
NCC-StC-K140	CTRP2	-2.4287	4.5689	-2.7405	84.9117
SNU-601	CTRP2	-1.7347	18.4488	-6.9844	54.5904
GCIY	GDSC2	-1.4842	6.5953	-3.782	38.8383
OCUM-1	GDSC2; CTRP2	-0.5813	22.9587	-7.9189	49.7816
NUGC-4	GDSC2; CTRP2	-0.3305	8.2614	-1.3716	48.2926
MKN74	CTRP2	-0.0587	19.9954	-6.0155	48.9742
HuG1-N	CTRP2	-0.0523	11.212	-2.1418	48.3286
MKN1	GDSC2; CTRP2	-0.0486	15.8005	-4.0869	48.0028
LMSU	CTRP2	0.3149	28.1611	-9.5507	48.5264
NCI-N87	GDSC2; CTRP2	0.4847	17.7652	-4.4423	46.5761
MKN28	GDSC2	0.7965	13.6163	-5.0998	33.6357
KATO III	GDSC2; CTRP2	1.0727	11.1815	-0.9399	42.269
SNU-216	CTRP2	1.2392	29.547	-9.3602	47.7246
NUGC-3	GDSC2; CTRP2	3.1251	14.6338	-0.3739	34.9388
GSU	CTRP2	3.3731	12.78	0.7329	32.6012
RERF-GC-1B	GDSC2	3.4699	16.6713	-4.4507	25.2185
SNU-1	GDSC2; CTRP2	3.9352	25.2843	-4.7937	38.8917
SNU-719	CTRP2	5.5186	17.5875	0.4396	27.789
SNU-668	CTRP2	6.692	13.7782	3.3654	15.8528
MKN45	GDSC2; CTRP2	7.9378	12.5627	4.9731	6.8157
KE-39	CTRP2	8.1116	18.5625	2.133	17.5422
MKN7	CTRP2	8.7461	28.7851	-2.4579	27.6986
Hs 746.T	GDSC2; CTRP2	8.7635	61.3864	-18.7227	40.3492
AGS	GDSC2; CTRP2	10.9572	26.3527	0.4078	17.7366
SNG-M	GDSC2; CTRP2	-11.6804	10.2341	-14.348	74.1842
SNU-685	CTRP2	-0.3181	8.8487	-1.5523	49.3511
SNU-1077	CTRP2	8.8275	21.811	1.0733	19.5625

Cancer Drug Sensitivity Data Curated from 17 Cell Line(s) in Thyroid Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
SW579	CTRP2	-10.1644	6.4726	-11.5868	76.801
K5	GDSC2	-6.6487	0.7655	-7.1909	69.569
8305C	GDSC2; CTRP2	-6.1101	9.1888	-7.9548	67.0823
IHH-4	GDSC2	-5.748	-2.0691	-5.7894	70.6261
HTC-C3	GDSC2	-4.0558	-0.3586	-4.1697	55.9411
FTC-238	CTRP2	-3.7489	-1.5816	-3.7489	71.942
CAL-62	GDSC2; CTRP2	-3.2407	7.4322	-4.2926	60.8345
ASH-3	GDSC2	-3.0002	6.8899	-5.4469	47.9949
B-CPAP	GDSC2; CTRP2	-2.9342	5.1305	-3.3916	61.303
TT	CTRP2	-1.1796	14.4397	-4.6566	52.3389
BHT-101	GDSC2; CTRP2	-0.6092	5.1744	-0.8842	49.5936
ML-1 [Human leukemia]	CTRP2	1.6567	95.0098	-41.5191	48.7615
WRO	GDSC2	1.8829	15.9571	-5.3544	31.2807
8505C	GDSC2; CTRP2	2.5348	15.655	-1.4324	38.3356
CGTH-W-1	CTRP2	3.766	19.4008	-2.0534	36.7017
TT2609-C02	GDSC2; CTRP2	4.1062	20.1007	-2.0819	35.3486
FTC-133	GDSC2; CTRP2	8.4115	40.7248	-8.6856	35.3251

Cancer Drug Sensitivity Data Curated from 45 Cell Line(s) in Upper Aerodigestive Tract Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
PE/CA-PJ15	CTRP2	-12.4187	22.28	-19.682	67.7959
BICR 6	CTRP2	-11.3175	25.8488	-20.0559	65.3014
PE/CA-PJ49	CTRP2	-9.4878	6.7726	-10.928	75.6792
HSC-2	GDSC2; CTRP2	-7.6828	3.83	-8.2804	76.0769
PE/CA-PJ34 (clone C12)	CTRP2	-7.2543	13.8411	-10.8355	66.2792
CAL-33	GDSC2; CTRP2	-6.8093	9.1963	-8.7177	68.4445
BICR 22	GDSC2; CTRP2	-5.9795	25.4661	-14.4414	58.9472
DOK	GDSC2	-5.7054	2.4999	-6.6387	63.2254
Ca9-22	GDSC2	-5.5471	-1.4982	-5.6223	68.3519
SCC-25	CTRP2	-5.5431	22.8206	-12.8083	59.4767
NCI-H3118	GDSC2	-5.4602	-3.4517	-5.461	70.3343
BB49-HNC	GDSC2	-5.1788	0.044	-5.4401	63.7077
BICR 10	GDSC2	-4.7338	0.4335	-5.034	60.4233
SCC-4	GDSC2; CTRP2	-4.5613	71.919	-35.5217	52.7743
HO-1-N-1	GDSC2	-4.4085	0.5689	-4.7091	58.0715
CAL-27	GDSC2; CTRP2	-4.3492	-3.0282	-4.3492	73.825
BICR 16	CTRP2	-3.603	20.8939	-9.976	57.8425
LB771-HNC	GDSC2	-3.1282	4.3556	-4.5121	48.3142
YD-10B	CTRP2	-2.4804	-1.8551	-2.4804	63.5531
SAS	GDSC2	-1.8625	7.6187	-4.6313	42.0396
BICR 18	CTRP2	-0.8755	9.5498	-2.3987	51.8523
PCI-04B	GDSC2	-0.8011	11.3636	-5.4118	39.1705
SAT [Human HNSCC]	GDSC2	-0.5611	10.7184	-4.8739	37.4325
SKN-3	GDSC2	-0.4853	9.3085	-4.1136	35.5595
Detroit 562	GDSC2; CTRP2	-0.4527	8.349	-1.5328	48.9065
SCC-9	GDSC2; CTRP2	-0.3544	101.5106	-46.5017	49.8255
OSC-20	GDSC2	0.3889	16.4652	-6.8739	37.7826
HSC-3	GDSC2; CTRP2	0.5696	14.5654	-2.9079	45.6309
BICR 56	CTRP2	0.6645	1795.8549	-892.6976	49.9808
SNU-1076	CTRP2	0.7767	16.1019	-3.3879	45.9758
SNU-1214	CTRP2	1.0691	7.2223	0.4698	41.1872
SCC-15	GDSC2	2.922	19.5716	-6.3198	30.8609
UPCI-SCC-090	GDSC2	3.0643	20.9656	-6.9018	31.6392
BICR 78	GDSC2	3.2323	15.7747	-4.1881	24.994
YD-8	CTRP2	3.4639	18.3458	-1.8227	37.1166
BICR 31	CTRP2	3.9971	18.4611	-1.3793	35.1229
JHU-022	GDSC2	5.1172	19.0412	-4.4033	21.6528
BHY	CTRP2	5.6613	20.8747	-1.0684	30.7864
PE/CA-PJ41 (clone D2)	CTRP2	6.2673	26.7371	-3.471	33.4831
SNU-899	CTRP2	7.2597	10.0544	5.6993	5.1394
SNU-46	CTRP2	7.8039	25.1237	-1.3855	27.2761
SNU-1066	CTRP2	7.8253	17.0224	2.6748	16.2055
FaDu	GDSC2; CTRP2	8.9477	29.7557	-2.7824	27.5353
SNU-1041	CTRP2	9.9877	17.527	3.988	7.9456
HSC-4	GDSC2; CTRP2	11.6559	28.4485	-0.118	18.1163

Cancer Drug Sensitivity Data Curated from 25 Cell Line(s) in Urinary Tract Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
JMSU-1	CTRP2	-6.3096	11.2813	-8.8782	66.4696
VM-CUB-1	CTRP2	-4.0138	37.5319	-18.1833	54.6333
RT-112	GDSC2; CTRP2	-3.0392	-0.9393	-3.0392	65.3015
U-BLC1	CTRP2	-2.2896	59.5954	-27.3776	51.6193
647V	GDSC2; CTRP2	-1.9962	6.0405	-2.5701	56.6677
CAL-29	GDSC2; CTRP2	-1.095	15.5236	-5.036	51.2677
BFTC-905	GDSC2; CTRP2	-0.646	44.7394	-18.5544	49.9606
5637	GDSC2; CTRP2	-0.5655	17.103	-5.1952	49.6724
SW780	GDSC2	-0.5141	7.5113	-3.2685	33.4058
RT-4	GDSC2; CTRP2	-0.3251	7.6378	-1.1723	48.1937
253J-BV	CTRP2	0.0409	10.1924	-1.6481	47.787
253J	CTRP2	0.1638	9.1951	-1.1511	47.0246
SCaBER	CTRP2	0.3407	34.3125	-12.5251	48.7399
T24	CTRP2	0.8074	20.553	-5.4287	46.6851
UM-UC-1	CTRP2	0.8999	142.2571	-65.7624	49.4745
UM-UC-3	CTRP2	0.9658	19.9288	-4.9792	46.134
BC-3C	CTRP2	1.3499	12.8695	-1.3633	42.6556
HT-1197	GDSC2; CTRP2	3.1952	14.6593	-0.317	34.6354
639V	GDSC2; CTRP2	3.2288	18.9949	-2.3591	37.7867
J82	GDSC2; CTRP2	7.5091	18.755	1.5566	20.0327
HT-1376	CTRP2	7.6658	24.0623	-0.9675	26.6675
SW1710	GDSC2; CTRP2	7.8309	38.4904	-8.043	35.5429
KU-19-19	GDSC2; CTRP2	9.8532	26.4033	-0.4219	21.4027
KMBC-2	CTRP2	10.9355	28.7557	-0.7807	21.0198
TCCSUP	GDSC2; CTRP2	11.7539	40.609	-6.0093	28.4514

Cancer Drug Sensitivity Data Curated from 26 Cell Line(s) in Urogenital System Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
PA-1	GDSC2	-6.9487	-2.5757	-7.0026	77.9824
NEC8	GDSC2	-6.1734	-2.2122	-6.2215	73.4353
C-33 A	GDSC2	-5.5674	-1.6443	-5.6312	68.7276
CAL-39	GDSC2	-4.9425	-2.8385	-4.9446	65.2525
SiSo	GDSC2	-4.8999	3.1737	-5.9819	58.8181
TC-YIK	GDSC2	-4.8198	-0.9115	-4.9144	62.4911
MS751	GDSC2	-4.1343	4.8418	-5.7722	54.0146
PWR-1E	GDSC2	-3.9234	5.1929	-5.6884	52.8332
DoTc2 4510	GDSC2	-3.6725	4.6621	-5.2109	51.5896
Ca Ski	GDSC2	-3.4301	15.2475	-9.7721	50.0931
DSH1	GDSC2	-3.1492	4.0129	-4.4007	48.3967
HeLa	GDSC2; CTRP2	-2.9246	1.4584	-2.9517	63.8542
BPH-1	GDSC2	-2.7946	9.0035	-6.1977	47.3805
PEO1	GDSC2	-2.3949	3.485	-3.393	42.6849
LB831-BLC	GDSC2	-0.4021	8.8243	-3.7998	34.4728
SKN	GDSC2	-0.191	6.9763	-2.7035	30.2421
C-4-I	GDSC2	-0.1431	11.0772	-4.6684	35.6086
OVMIU	GDSC2	0.1006	9.68	-3.7576	32.5585
HEY	GDSC2	0.7768	10.1834	-3.405	29.2412
OVCA420	GDSC2	1.2027	3.509	0.2884	9.3913
ME-180	GDSC2	1.3209	12.8573	-4.2727	30.1512
SW756	GDSC2	3.0577	7.3773	-0.1949	7.5792
HT-3	GDSC2	3.3764	5.677	0.7686	1.7451
SKG-IIIa	GDSC2	3.5797	17.5852	-4.8196	25.9932
HEC-1	GDSC2	3.812	17.4591	-4.5811	24.8338
SiHa	GDSC2	4.2408	20.4156	-5.719	26.8435

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Vincristine

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Clofarabine	DMCVJ86	Moderate	Increased risk of hepatotoxicity by the combination of Vincristine and Clofarabine.	Mature B-cell lymphoma [2A85]	[12]
Blinatumomab	DMGECIJ	Moderate	Decreased metabolism of Vincristine caused by Blinatumomab mediated inhibition of CYP450 enzyme.	Mature B-cell lymphoma [2A85]	[13]

Coadministration of a Drug Treating the Disease Different from Vincristine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Remdesivir	DMBFZ6L	Moderate	Increased risk of hepatotoxicity by the combination of Vincristine and Remdesivir.	1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]	[14]
Ivosidenib	DM8S6T7	Moderate	Increased metabolism of Vincristine caused by Ivosidenib mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[15]
Midostaurin	DMI6E0R	Moderate	Decreased clearance of Vincristine due to the transporter inhibition by Midostaurin.	Acute myeloid leukaemia [2A60]	[16]
Arn-509	DMT81LZ	Moderate	Accelerated clearance of Vincristine due to the transporter induction by Arn-509.	Acute myeloid leukaemia [2A60]	[16]
Gilteritinib	DMTI0ZO	Moderate	Decreased clearance of Vincristine due to the transporter inhibition by Gilteritinib.	Acute myeloid leukaemia [2A60]	[17]
Siltuximab	DMGEATB	Moderate	Additive immunosuppressive effects by the combination of Vincristine and Siltuximab.	Anemia [3A00-3A9Z]	[16]
Dronedarone	DMA8FS5	Moderate	Decreased clearance of Vincristine due to the transporter inhibition by Dronedarone.	Angina pectoris [BA40]	[18]
Bedaquiline	DM3906J	Moderate	Increased risk of hepatotoxicity by the combination of Vincristine and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[19]
Voriconazole	DMAOL2S	Major	Decreased clearance of Vincristine due to the transporter inhibition by Voriconazole.	Aspergillosis [1F20]	[20]
Posaconazole	DMUL5EW	Major	Decreased clearance of Vincristine due to the transporter inhibition by Posaconazole.	Aspergillosis [1F20]	[20]
Roflumilast	DMPGHY8	Moderate	Additive immunosuppressive effects by the combination of Vincristine and Roflumilast.	Asthma [CA23]	[16]
Ofloxacin	DM0VQN3	Minor	Decreased absorption of Vincristine due to intestinal mucosa variation caused by Ofloxacin.	Bacterial infection [1A00-1C4Z]	[21]
Dalfopristin	DM4LTKV	Moderate	Decreased metabolism of Vincristine caused by Dalfopristin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[22]
Clarithromycin	DM4M1SG	Major	Decreased clearance of Vincristine due to the transporter inhibition by Clarithromycin.	Bacterial infection [1A00-1C4Z]	[20]
Trovafloxacin	DM6AN32	Minor	Decreased absorption of Vincristine due to intestinal mucosa variation caused by Trovafloxacin.	Bacterial infection [1A00-1C4Z]	[21]
Sparfloxacin	DMB4HCT	Minor	Decreased absorption of Vincristine due to intestinal mucosa variation caused by Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[21]
Gemifloxacin	DMHT34O	Minor	Decreased absorption of Vincristine due to intestinal mucosa variation caused by Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[21]
Norfloxacin	DMIZ6W2	Minor	Decreased absorption of Vincristine due to intestinal mucosa variation caused by Norfloxacin.	Bacterial infection [1A00-1C4Z]	[21]
ABT-492	DMJFD2I	Minor	Decreased absorption of Vincristine due to intestinal mucosa variation caused by ABT-492.	Bacterial infection [1A00-1C4Z]	[21]
Levofloxacin	DMS60RB	Minor	Decreased absorption of Vincristine due to intestinal mucosa variation caused by Levofloxacin.	Bacterial infection [1A00-1C4Z]	[21]
Troleandomycin	DMUZNIG	Major	Decreased clearance of Vincristine due to the transporter inhibition by Troleandomycin.	Bacterial infection [1A00-1C4Z]	[20]
Lomefloxacin	DMVRH9C	Minor	Decreased absorption of Vincristine due to intestinal mucosa variation caused by Lomefloxacin.	Bacterial infection [1A00-1C4Z]	[21]
Telithromycin	DMZ4P3A	Major	Decreased clearance of Vincristine due to the transporter inhibition by Telithromycin.	Bacterial infection [1A00-1C4Z]	[20]
Erdafitinib	DMI782S	Moderate	Decreased clearance of Vincristine due to the transporter inhibition by Erdafitinib.	Bladder cancer [2C94]	[23]
Pexidartinib	DMS2J0Z	Major	Increased risk of hepatotoxicity by the combination of Vincristine and Pexidartinib.	Bone/articular cartilage neoplasm [2F7B]	[24]
Lomustine	DMMWSUL	Minor	Decreased metabolism of Vincristine caused by Lomustine mediated inhibition of CYP450 enzyme.	Brain cancer [2A00]	[25]
Lapatinib	DM3BH1Y	Moderate	Decreased clearance of Vincristine due to the transporter inhibition by Lapatinib.	Breast cancer [2C60-2C6Y]	[26]
Tucatinib	DMBESUA	Major	Decreased clearance of Vincristine due to the transporter inhibition by Tucatinib.	Breast cancer [2C60-2C6Y]	[20]
Palbociclib	DMD7L94	Moderate	Decreased metabolism of Vincristine caused by Palbociclib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[27]
Capecitabine	DMTS85L	Minor	Increased plasma concentrations of Vincristine and Capecitabine due to competitive inhibition of the same metabolic pathway.	Colorectal cancer [2B91]	[25]
Mifepristone	DMGZQEF	Moderate	Decreased metabolism of Vincristine caused by Mifepristone mediated inhibition of CYP450 enzyme.	Cushing syndrome [5A70]	[16]
Ivacaftor	DMZC1HS	Moderate	Decreased clearance of Vincristine due to the transporter inhibition by Ivacaftor.	Cystic fibrosis [CA25]	[28]
MK-8228	DMOB58Q	Moderate	Decreased metabolism of Vincristine caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[29]
Aprepitant	DM053KT	Moderate	Decreased metabolism of Vincristine caused by Aprepitant mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[30]
Nefazodone	DM4ZS8M	Major	Decreased metabolism of Vincristine caused by Nefazodone mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[20]
Primidone	DM0WX6I	Moderate	Increased metabolism of Vincristine caused by Primidone mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[31]
Oxcarbazepine	DM5PU6O	Moderate	Increased metabolism of Vincristine caused by Oxcarbazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[32]
Cenobamate	DM8KLU9	Moderate	Increased metabolism of Vincristine caused by Cenobamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[33]
Fosphenytoin	DMOX3LB	Moderate	Accelerated clearance of Vincristine due to the transporter induction by Fosphenytoin.	Epilepsy/seizure [8A61-8A6Z]	[34]
Rufinamide	DMWE60C	Moderate	Increased metabolism of Vincristine caused by Rufinamide mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[16]
Phenobarbital	DMXZOCG	Moderate	Increased metabolism of Vincristine caused by Phenobarbital mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[31]
Carbamazepine	DMZOLBI	Moderate	Accelerated clearance of Vincristine due to the transporter induction by Carbamazepine.	Epilepsy/seizure [8A61-8A6Z]	[31]
Cannabidiol	DM0659E	Moderate	Increased risk of hepatotoxicity by the combination of Vincristine and Cannabidiol.	Epileptic encephalopathy [8A62]	[16]
Tazemetostat	DMWP1BH	Moderate	Increased metabolism of Vincristine caused by Tazemetostat mediated induction of CYP450 enzyme.	Follicular lymphoma [2A80]	[35]
Itraconazole	DMCR1MV	Major	Decreased metabolism of Vincristine caused by Itraconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[20]
Miconazole	DMPMYE8	Moderate	Decreased metabolism of Vincristine caused by Miconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[36]
Ketoconazole	DMPZI3Q	Major	Decreased metabolism of Vincristine caused by Ketoconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[20]
Boceprevir	DMBSHMF	Major	Decreased metabolism of Vincristine caused by Boceprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[20]
Telaprevir	DMMRV29	Major	Decreased clearance of Vincristine due to the transporter inhibition by Telaprevir.	Hepatitis virus infection [1E50-1E51]	[20]
Rifampin	DMA8J1G	Moderate	Accelerated clearance of Vincristine due to the transporter induction by Rifampin.	HIV-infected patients with tuberculosis [1B10-1B14]	[31]
Rifapentine	DMCHV4I	Moderate	Accelerated clearance of Vincristine due to the transporter induction by Rifapentine.	HIV-infected patients with tuberculosis [1B10-1B14]	[31]
Brentuximab vedotin	DMWLC57	Moderate	Increased risk of hepatotoxicity by the combination of Vincristine and Brentuximab vedotin.	Hodgkin lymphoma [2B30]	[37]
Delavirdine	DM3NF5G	Major	Decreased metabolism of Vincristine caused by Delavirdine mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[20]
Fosamprenavir	DM4W9B3	Major	Decreased metabolism of Vincristine caused by Fosamprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[20]
Cobicistat	DM6L4H2	Major	Decreased clearance of Vincristine due to the transporter inhibition by Cobicistat.	Human immunodeficiency virus disease [1C60-1C62]	[20]
Efavirenz	DMC0GSJ	Moderate	Increased metabolism of Vincristine caused by Efavirenz mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[38]
Saquinavir	DMG814N	Major	Decreased metabolism of Vincristine caused by Saquinavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[20]
Etravirine	DMGV8QU	Moderate	Increased metabolism of Vincristine caused by Etravirine mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[39]
Zalcitabine	DMH7MUV	Moderate	Increased risk of peripheral neuropathy by the combination of Vincristine and Zalcitabine.	Human immunodeficiency virus disease [1C60-1C62]	[40]
Amprenavir	DMLMXE0	Major	Decreased metabolism of Vincristine caused by Amprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[20]
Darunavir	DMN3GCH	Moderate	Decreased metabolism of Vincristine caused by Darunavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[41]
Atazanavir	DMSYRBX	Major	Decreased metabolism of Vincristine caused by Atazanavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[20]
Mipomersen	DMGSRN1	Major	Increased risk of hepatotoxicity by the combination of Vincristine and Mipomersen.	Hyper-lipoproteinaemia [5C80]	[42]
Teriflunomide	DMQ2FKJ	Major	Increased risk of hepatotoxicity by the combination of Vincristine and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[43]
BMS-201038	DMQTAGO	Major	Increased risk of hepatotoxicity by the combination of Vincristine and BMS-201038.	Hyper-lipoproteinaemia [5C80]	[44]
Verapamil	DMA7PEW	Minor	Increased plasma concentration of Vincristine and Verapamil due to competitive binding of plasma proteins.	Hypertension [BA00-BA04]	[45]
Conivaptan	DM1V329	Major	Decreased metabolism of Vincristine caused by Conivaptan mediated inhibition of CYP450 enzyme.	Hypo-osmolality/hyponatraemia [5C72]	[20]
Tolvaptan	DMIWFRL	Moderate	Decreased clearance of Vincristine due to the transporter inhibition by Tolvaptan.	Hypo-osmolality/hyponatraemia [5C72]	[17]
Berotralstat	DMWA2DZ	Moderate	Decreased metabolism of Vincristine caused by Berotralstat mediated inhibition of CYP450 enzyme.	Innate/adaptive immunodeficiency [4A00]	[46]
Amobarbital	DM0GQ8N	Moderate	Increased metabolism of Vincristine caused by Amobarbital mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[31]
Methotrexate	DM2TEOL	Moderate	Increased risk of hepatotoxicity by the combination of Vincristine and Methotrexate.	Leukaemia [2A60-2B33]	[16]
Glycerol phenylbutyrate	DMDGRQO	Moderate	Increased metabolism of Vincristine caused by Glycerol phenylbutyrate mediated induction of CYP450 enzyme.	Liver disease [DB90-DB9Z]	[16]
Denosumab	DMNI0KO	Moderate	Additive myelosuppressive effects by the combination of Vincristine and Denosumab.	Low bone mass disorder [FB83]	[47]
Crizotinib	DM4F29C	Moderate	Decreased metabolism of Vincristine caused by Crizotinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[48]
Brigatinib	DM7W94S	Moderate	Increased metabolism of Vincristine caused by Brigatinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[49]
Ceritinib	DMB920Z	Major	Decreased metabolism of Vincristine caused by Ceritinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[20]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Vincristine caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[50]
Osimertinib	DMRJLAT	Moderate	Increased metabolism of Vincristine caused by Osimertinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[16]
Capmatinib	DMYCXKL	Moderate	Decreased clearance of Vincristine due to the transporter inhibition by Capmatinib.	Lung cancer [2C25]	[51]
Selpercatinib	DMZR15V	Moderate	Decreased metabolism of Vincristine caused by Selpercatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[16]
Calaspargase pegol	DMQZBXI	Moderate	Increased risk of hepatotoxicity by the combination of Vincristine and Calaspargase pegol.	Malignant haematopoietic neoplasm [2B33]	[52]
Idelalisib	DM602WT	Major	Decreased metabolism of Vincristine caused by Idelalisib mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[20]
IPI-145	DMWA24P	Moderate	Decreased metabolism of Vincristine caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[53]
LGX818	DMNQXV8	Moderate	Increased metabolism of Vincristine caused by LGX818 mediated induction of CYP450 enzyme.	Melanoma [2C30]	[54]
Dabrafenib	DMX6OE3	Moderate	Increased metabolism of Vincristine caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[16]
Lasmiditan	DMXLVDT	Moderate	Decreased clearance of Vincristine due to the transporter inhibition by Lasmiditan.	Migraine [8A80]	[55]
Exjade	DMHPRWG	Moderate	Decreased metabolism of Vincristine caused by Exjade mediated inhibition of CYP450 enzyme.	Mineral absorption/transport disorder [5C64]	[56]
Thalidomide	DM70BU5	Major	Additive thrombogenic effects by the combination of Vincristine and Thalidomide.	Multiple myeloma [2A83]	[57]
Tecfidera	DM2OVDT	Moderate	Additive immunosuppressive effects by the combination of Vincristine and Tecfidera.	Multiple sclerosis [8A40]	[58]
Siponimod	DM2R86O	Major	Additive immunosuppressive effects by the combination of Vincristine and Siponimod.	Multiple sclerosis [8A40]	[17]
Fingolimod	DM5JVAN	Major	Additive immunosuppressive effects by the combination of Vincristine and Fingolimod.	Multiple sclerosis [8A40]	[59]
Ocrelizumab	DMEZ2KH	Moderate	Additive immunosuppressive effects by the combination of Vincristine and Ocrelizumab.	Multiple sclerosis [8A40]	[60]
Ozanimod	DMT6AM2	Major	Additive immunosuppressive effects by the combination of Vincristine and Ozanimod.	Multiple sclerosis [8A40]	[16]
Rifabutin	DM1YBHK	Moderate	Increased metabolism of Vincristine caused by Rifabutin mediated induction of CYP450 enzyme.	Mycobacterium infection [1B10-1B21]	[31]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Vincristine caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[16]
Nilotinib	DM7HXWT	Moderate	Decreased clearance of Vincristine due to the transporter inhibition by Nilotinib.	Myeloproliferative neoplasm [2A20]	[61]
Imatinib	DM7RJXL	Moderate	Decreased metabolism of Vincristine caused by Imatinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[62]
Dasatinib	DMJV2EK	Moderate	Decreased metabolism of Vincristine caused by Dasatinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[63]
Omacetaxine mepesuccinate	DMPU2WX	Moderate	Additive immunosuppressive effects by the combination of Vincristine and Omacetaxine mepesuccinate.	Myeloproliferative neoplasm [2A20]	[64]
Modafinil	DMYILBE	Minor	Increased metabolism of Vincristine caused by Modafinil mediated induction of CYP450 enzyme.	Narcolepsy [7A20]	[65]
Rolapitant	DM8XP26	Moderate	Decreased clearance of Vincristine due to the transporter inhibition by Rolapitant.	Nausea/vomiting [MD90]	[66]
Entrectinib	DMMPTLH	Moderate	Decreased metabolism of Vincristine caused by Entrectinib mediated inhibition of CYP450 enzyme.	Non-small cell lung cancer [2C25]	[67]
Rucaparib	DM9PVX8	Moderate	Decreased metabolism of Vincristine caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[68]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Vincristine caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[69]
Lefamulin	DME6G97	Moderate	Decreased metabolism of Vincristine caused by Lefamulin mediated inhibition of CYP450 enzyme.	Pneumonia [CA40]	[70]
Lonafarnib	DMGM2Z6	Major	Decreased metabolism of Vincristine caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[20]
Enzalutamide	DMGL19D	Moderate	Accelerated clearance of Vincristine due to the transporter induction by Enzalutamide.	Prostate cancer [2C82]	[71]
Ustekinumab	DMHTYK3	Moderate	Additive myelosuppressive effects by the combination of Vincristine and Ustekinumab.	Psoriasis [EA90]	[16]
Tildrakizumab	DMLW9HG	Moderate	Additive myelosuppressive effects by the combination of Vincristine and Tildrakizumab.	Psoriasis [EA90]	[16]
Risankizumab	DMM32GT	Moderate	Additive immunosuppressive effects by the combination of Vincristine and Risankizumab.	Psoriasis [EA90]	[16]
Ixekizumab	DMXW92T	Moderate	Additive myelosuppressive effects by the combination of Vincristine and Ixekizumab.	Psoriasis [EA90]	[16]
Bosentan	DMIOGBU	Moderate	Increased metabolism of Vincristine caused by Bosentan mediated induction of CYP450 enzyme.	Pulmonary hypertension [BB01]	[72]
Temsirolimus	DMS104F	Moderate	Increased plasma concentrations of Vincristine and Temsirolimus due to competitive inhibition of the same metabolic pathway.	Renal cell carcinoma [2C90]	[73]
Gatifloxacin	DMSL679	Minor	Decreased absorption of Vincristine due to intestinal mucosa variation caused by Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[21]
Tocilizumab	DM7J6OR	Moderate	Additive immunosuppressive effects by the combination of Vincristine and Tocilizumab.	Rheumatoid arthritis [FA20]	[16]
Canakinumab	DM8HLO5	Moderate	Additive myelosuppressive effects by the combination of Vincristine and Canakinumab.	Rheumatoid arthritis [FA20]	[16]
Rilonacept	DMGLUQS	Moderate	Additive immunosuppressive effects by the combination of Vincristine and Rilonacept.	Rheumatoid arthritis [FA20]	[16]
Golimumab	DMHZV7X	Major	Additive immunosuppressive effects by the combination of Vincristine and Golimumab.	Rheumatoid arthritis [FA20]	[74]
Dexamethasone	DMMWZET	Moderate	Increased metabolism of Vincristine caused by Dexamethasone mediated induction of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[31]
Sarilumab	DMOGNXY	Moderate	Additive myelosuppressive effects by the combination of Vincristine and Sarilumab.	Rheumatoid arthritis [FA20]	[16]
Leflunomide	DMR8ONJ	Major	Additive myelosuppressive effects by the combination of Vincristine and Leflunomide.	Rheumatoid arthritis [FA20]	[43]
Anthrax vaccine	DM9GSWY	Moderate	Antagonize the effect of Vincristine when combined with Anthrax vaccine.	Sepsis [1G40-1G41]	[75]
Voxelotor	DMCS6M5	Moderate	Decreased metabolism of Vincristine caused by Voxelotor mediated inhibition of CYP450 enzyme.	Sickle-cell disorder [3A51]	[76]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Vincristine caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[16]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Vincristine caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[17]
Armodafinil	DMGB035	Minor	Increased metabolism of Vincristine caused by Armodafinil mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[65]
LEE011	DMMX75K	Moderate	Decreased metabolism of Vincristine caused by LEE011 mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[77]
Etoposide	DMNH3PG	Minor	Decreased metabolism of Vincristine caused by Etoposide mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[25]
Fluorouracil	DMUM7HZ	Minor	Increased plasma concentrations of Vincristine and Fluorouracil due to competitive inhibition of the same metabolic pathway.	Solid tumour/cancer [2A00-2F9Z]	[25]
Doxorubicin	DMVP5YE	Minor	Decreased metabolism of Vincristine caused by Doxorubicin mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[25]
Pitolisant	DM8RFNJ	Moderate	Increased metabolism of Vincristine caused by Pitolisant mediated induction of CYP450 enzyme.	Somnolence [MG42]	[16]
Naltrexone	DMUL45H	Moderate	Increased risk of hepatotoxicity by the combination of Vincristine and Naltrexone.	Substance abuse [6C40]	[78]
Fostamatinib	DM6AUHV	Moderate	Decreased metabolism of Vincristine caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[79]
Brilinta	DMBR01X	Moderate	Decreased metabolism of Vincristine caused by Brilinta mediated inhibition of CYP450 enzyme.	Thrombosis [DB61-GB90]	[16]
Sirolimus	DMGW1ID	Moderate	Increased plasma concentrations of Vincristine and Sirolimus due to competitive inhibition of the same metabolic pathway.	Transplant rejection [NE84]	[73]
Azathioprine	DMMZSXQ	Moderate	Additive myelosuppressive effects by the combination of Vincristine and Azathioprine.	Transplant rejection [NE84]	[17]
Tacrolimus	DMZ7XNQ	Moderate	Increased plasma concentrations of Vincristine and Tacrolimus due to competitive inhibition of the same metabolic pathway.	Transplant rejection [NE84]	[73]
Cinoxacin	DM4EWNS	Minor	Decreased absorption of Vincristine due to intestinal mucosa variation caused by Cinoxacin.	Urinary tract infection [GC08]	[21]
Nalidixic acid	DMRM0JV	Minor	Decreased absorption of Vincristine due to intestinal mucosa variation caused by Nalidixic acid.	Urinary tract infection [GC08]	[21]
Ganciclovir	DM1MBYQ	Moderate	Additive myelosuppressive effects by the combination of Vincristine and Ganciclovir.	Virus infection [1A24-1D9Z]	[17]
Valganciclovir	DMS2IUH	Moderate	Additive myelosuppressive effects by the combination of Vincristine and Valganciclovir.	Virus infection [1A24-1D9Z]	[17]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6785).
• [2] Vincristine FDA Label
• [3] BDDCS applied to over 900 drugs
• [4] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [5] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [6] Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
• [7] Interaction of plant cannabinoids with the multidrug transporter ABCC1 (MRP1). Eur J Pharmacol. 2008 Sep 4;591(1-3):128-31.
• [8] Mutant Gly482 and Thr482 ABCG2 mediate high-level resistance to lipophilic antifolates. Cancer Chemother Pharmacol. 2006 Dec;58(6):826-34.
• [9] L-type calcium channel blockers reverse docetaxel and vincristine-induced multidrug resistance independent of ABCB1 expression in human lung cancer cell lines. Toxicol Lett. 2010 Feb 15;192(3):408-18.
• [10] Association of CYP3A5 expression and vincristine neurotoxicity in pediatric malignancies in Turkish population. J Pediatr Hematol Oncol. 2017 Aug;39(6):458-462.
• [11] Drug Interactions Flockhart Table
• [12] Product Information. Clolar (clofarabine). sanofi-aventis, Bridgewater, NJ.
• [13] Product Information. Blincyto (blinatumomab). Amgen USA, Thousand Oaks, CA.
• [14] European Medicines Agency "Summary on compassionate use. Remdesivir Gilead.".
• [15] Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
• [16] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [17] Cerner Multum, Inc. "Australian Product Information.".
• [18] Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ.
• [19] Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
• [20] Antoniou T, Tseng AL "Interactions between antiretrovirals and antineoplastic drug therapy." Clin Pharmacokinet 44 (2005): 111-145. [PMID: 15656694]
• [21] Johnson EJ, MacGowan AP, Potter MN, et al "Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy." J Antimicrob Chemother 25 (1990): 837-42. [PMID: 2373666]
• [22] Product Information. Synercid (dalfopristin-quinupristin) Rhone-Poulenc Rorer, Collegeville, PA.
• [23] Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
• [24] Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
• [25] Product Information. Oncovin (vincristine). Lilly, Eli and Company, Indianapolis, IN.
• [26] Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
• [27] Product Information. Ibrance (palbociclib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [28] Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
• [29] Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
• [30] Charasson V, Haaz MC, Robert J "Determination of Drug Interactions Occurring with the Metabolic Pathways of Irinotecan." Drug Metab Dispos 30 (2002): 731-733. [PMID: 12019202]
• [31] Product Information. Marqibo (vinCRIStine liposome). Talon Therapeutics Inc, South San Francisco,, CA.
• [32] Product Information. Trileptal (oxcarbazepine) Novartis Pharmaceuticals, East Hanover, NJ.
• [33] Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
• [34] Bollini P, Riva R, Albani F, Ida et al "Decreased phenytoin level during antineoplastic therapy: a case report." Epilepsia 24 (1983): 75-8. [PMID: 6822234]
• [35] Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
• [36] Product Information. ORAVIG (miconazole). Strativa Pharmaceuticals, a Division of Par Pharmaceuticals, Inc., Woodcliff Lake, NJ.
• [37] Product Information. Accolate (zafirlukast). Zeneca Pharmaceuticals, Wilmington, DE.
• [38] Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE.
• [39] Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
• [40] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6. [PMID: 219931]
• [41] Product Information. Prezista (darunavir). Ortho Biotech Inc, Bridgewater, NJ.
• [42] Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
• [43] Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
• [44] Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
• [45] Abdel-Rahman M, Wosch F, Harder S, Woodcock BG "Interaction between verapamil and vincristine binding to plasma proteins." Int J Clin Pharmacol Ther Toxicol 30 (1992): 536-7. [PMID: 1490822]
• [46] Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
• [47] Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
• [48] Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [49] Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
• [50] Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [51] Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
• [52] Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
• [53] Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
• [54] Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
• [55] Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
• [56] Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
• [57] Bennett CL, Nebeker JR, Samore MH, et al "The Research on Adverse Drug Events and Reports (RADAR) project." JAMA 293 (2005): 2131-40. [PMID: 15870417]
• [58] Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
• [59] Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
• [60] Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
• [61] Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
• [62] Product Information. Gleevec (imatinib mesylate). Novartis Pharmaceuticals, East Hanover, NJ.
• [63] Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
• [64] Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
• [65] Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
• [66] Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
• [67] Product Information. Rozlytrek (entrectinib). Genentech, South San Francisco, CA.
• [68] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
• [69] Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
• [70] Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
• [71] Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
• [72] Product Information. Tracleer (bosentan). Acetelion Pharmaceuticals US, Inc, South San Francisco, CA.
• [73] Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
• [74] Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
• [75] CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
• [76] Product Information. Oxbryta (voxelotor). Global Blood Therapeutics, Inc., South San Francisco, CA.
• [77] DSouza DL, Levasseur LM, Nezamis J, Robbins DK, Simms L, Koch KM "Effect of alosetron on the pharmacokinetics of alprazolam." J Clin Pharmacol 41 (2001): 452-4. [PMID: 11304902]
• [78] Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.
• [79] Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.